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CHAPTER I 
INTRODUCTION
1-26 
 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
Analytical chemistry has been defined as the science of determining the composition 
of materials in terms of the elements or compounds contained in the samples. The main goal 
of the analytical chemistry is to gather information about qualitative as well as quantitative 
compositions of chemical substances. 
 
Pharmaceutical analysis deals with the analysis (qualification and quantification) of 
pharmaceutical substances. Pharmaceutical analyst in research and development (R&D) of 
pharmaceutical industry play an inevitable part in the development of a new drug product or 
a molecule and to follow up the activities to assure that, a new product meets the established 
standard and quality throughout its shelf life. 
 
Before submitting a drug product for approval to the regulatory authority, all the 
batches of the products should comply with the specific standards. It is the duty of the 
pharmaceutical analyst in quality control (QC) and quality assurance (QA) departments to 
check whether it is complying with the standard or not. The methods are generally 
developed in the analytical R&D and to QC department or other departments. 
 
Quality Assurance and Quality Control plays a key role in developing the safety and 
efficacy of the drugs. A highly specific and sensitive analytical technique holds the key to 
design, development, standardization and quality control of drug products. This is very 
much important in pharmacokinetics and metabolism of drugs, and is very much essential 
for the determination of bioavailability.  
 
The pharmaceutical analyst plays a vital role in assuring the identity, safety, efficacy 
and quality of the drug products. Safety and efficacy study require that drug substances and 
drug product meet two critical appropriate requirements 
 
 Established identity and purity 
 Established bioavailability and dissolution 
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Common techniques for analysis
2-3
 
The main techniques employed for quantitative analysis are based upon, 
a) Suitable chemical reaction based on either the amount of reagent needed to complete 
the reactions or the amount of reaction product obtained. 
Eg : Neutralization, Complex metric titration, Precipitation titration, Redo titration 
b) Appropriate electrical measurements, which involves the measurement of current, 
voltage or resistance in relation to the concentration of a certain species in solution. 
Eg : Voltammeter, Potentiometer, Conductometry 
c) The measurement of certain optical properties which depends either upon 
- Measurement of the amount of radiant energy of a particular wavelength of a 
particular wavelength absorbed by the sample 
- On the emission of radiant energy and measurement of the amount of energy of a 
particular wavelength emitted. 
Eg: Visible spectrophotometry, Ultraviolet spectrophotometry, Infrared 
 spectrophotometry 
Separation process employed for the separation of mixture of substances and 
for the identification of components 
d)  Chromatography 
Eg: Gas chromatography, HPLC, HPTLC 
e) X-ray methods 
When high-speed electrons collide with a solid target, X-rays are produced. 
From the remittent x-ray emission, it is possible to identify certain emission peaks, 
which are characteristics of elements contained in the target. The wavelength of the 
peaks can be related to the atomic numbers of the elements producing them. 
f) Radioactivity  
The intensity of a radiation from a naturally radioactive substances or an 
induced radioactive substance arising from the exposure of the sample to a neutrons 
source is measured. 
g) Mass spectroscopy 
Sample to be determined are bombarded under a high energy electron beam. 
The formed fragments are separated by electric and/or magnetic field based on their 
m/e ratio and to determine their molecular mass. 
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h) Optical methods 
I. Refractometer  - refractive index of liquids are determined 
II. Optical rotation- for the determination of optically active compounds 
i) Thermal methods 
It keeps temperature as a function to measure the changes 
Eg : Thermogravimetry, Differential scanning calorimetry, Differential thermal 
analysis, Thermo mechanical analysis 
 
Types of HPLC Methods
7
 
 Normal phase Chromatography 
 Reverse-Phase Chromatography 
 Ion exchange Chromatography 
 Affinity Chromatography 
 Size exclusion Chromatography 
 
Normal Phase Chromatography
10
 
Normal phase chromatography is the technique where, the stationary phase is polar 
and the mobile phase is non-polar (organic solvents). In this phase the less polar component 
will elute faster than the more polar components. Normal phase chromatography is very 
much similar to thin layer chromatography or column chromatography. Even though this is 
termed as normal phase, it is not the most widely used chromatographic technique. The 
column should be filled with tiny silica particles and the solvents used are non-polar. A 
normal phase column usually has an internal diameter of 4.6 mm and a length of about               
150 -200 mm. in this case more polar compounds will show more affinity towards stationary 
phase and will take more time to elute. The non-polar compounds will elute faster. The            
non-polar drugs are usually estimated by this normal phase chromatographic method. 
 
Reverse-Phase Chromatography 
RP-HPLC is the most widely used HPLC technique in the pharmaceutical analysis, 
because compounds will elute faster with high resolution. In this technique, the non-polar 
stationary phase and polar solvents are used. Usually polar drugs are analyzed by this 
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technique. Here the more polar compounds will elute faster because of its less affinity 
towards the stationary phase. The separation is based on the strength of the solvent, column 
temperature, pH etc. The RP-HPLC method is the most widely used mode of HPLC. 
 
Normal Phase Chromatography Vs Reverse-Phase Chromatography 
The adsorption of analyte to the stationary phase is by hydrophobic effect in RP-
HPLC method. The reverse phase indicates that the stationary phase is less polar than the 
solvent and the normal phase indicates that the stationary phase is more polar than the 
solvent. In general, adsorption of a solute to reverse phase is by hydrogen bonding between 
the solute and stationary phase.  
 
Normal phase – Non-polar Mobile Phase: Polar Stationary Phase  
Reverse Phase- Polar Mobile Phase: Non-Polar Stationary Phase 
 
In RP-HPLC, solute retention is mainly due to hydrophobic interaction between the 
solute and the non-polar hydrocarbon stationary phase. The non-polar components of the 
sample interact more with the relatively non-polar hydrocarbon column packing and thus 
elute than the polar components. The hydrogen bonding predominates than any other 
interactions in the normal phase. The elution of solutes is in the order of decreasing polarity 
in RP-HPLC method, i.e, increasing hydrophobicity, while in mobile phase the least polar 
compound will elute first. Before beginning with actual experimentation, it would be 
advantageous to view method development from a broader perspective. The method 
development process can be visualized from a high-level map perspective better to define 
the general steps encountered to achieving the end product, a stability-indicating method. 
 
QUANTITATION 
Quantitation methods in HPLC
25
: 
From the detector signals, the peak height and peak area can be measured. This 
measurement will give an account about the concentration or mass of the compound. To 
establish this, some sort of calibration should be performed. 
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The primary techniques for quantitation are: 
1. Normalized peak area method 
2. External standard method 
3. Internal standard method 
4. Method of standard addition 
 
1. Normalized peak area method 
The peak area of any one of the peak is referred to the normalized peak area. To 
determine the degradation product or impurity in a product, this method is used. The 
response factor for each component is identified in this method. 
 
2. External standard method 
Both standard and unknown samples are injected inn this method. The unknown can 
be determined from a calibration graph or from calculating response factor. 
The response factor Rf can be calculated from the following formula- 
                                      
                             Rf =  
ionConcentratdardS
heightPeakAreadardS
tan
)(tan
     
If there is no extensive sample preparation is needed. The external standard method 
id preferred. The chromatographic conditions should be maintained constant during the 
separation of all standards and samples for the better quantition using external standard 
method. External standard methods are mainly used to ensure that the total 
chromatographic system is performing properly and can provide reliable results. 
 
3. Internal Standard Method 
A compound which is differ from analyte is used as the internal standard. But that 
compound should be well resolved in the separation. The purpose of internal standard is 
just to mimic the nature and behavior of the sample. Mainly the internal standard is used 
for the compounds which needs a pre-treatment or preparation. 
 
To determine the concentration of sample component in the original sample, the 
Response Factor is used. Response Factor is defined as the ratio of peak area of sample 
component (Ax) and the internal standard (AISTD). The formula is as follows, 
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                                      Rf  =  
std
x
AI
A
  
     Based on the response factor and strength of the internal standard (NISTD), the 
amount of    the analyte in the original sample can be calculated from the formula, 
 
X  =  STD
ISTDF
x N
AR
A


  
 
4. Method Of Standard Addition 
The method of standard addition can be used to provide a calibration plot for the 
quantitative analysis. Trace analysis is making use of this method mostly. An important 
aspect of this method is that the response prior to spiking additional analytes should be 
high enough to provide a reasonable S/N ratio (>10), otherwise the result will have poor 
precision. 
 
Reason for selecting HPLC
11
 
1. A wide variety of packing material are available, which allows the separation of most of 
the compounds. The phases that are most commonly used for the drug substances of low 
molecular weight (< 1000) and their metabolites or degradants are the absorption 
systems based on silica and the reversed phase systems based on octyl silyl or octa decyl 
silyl bonded on silica. 
2. A good choice of detectors are available which permit the sensitive detection of most 
chemical type, and the accuracy and precision with which eluted substances may be 
quantified give analytical data of the highest caliber. 
3. Since the size of the packaging materials are in micron size, they will provide an 
excellent separation. 
4. Since a standard analytical column provide about 5000-10000 theoretical plate, it 
provides adequate resolution for the effective separation of the compound. 
5. For routine analysis, we can use short columns (3-10cm) which facilitates a faster 
separation within a short time. Combination of HPLC along with some 
spectrophotometric techniques(UV,IR,MS) can achieve a good range of separation. 
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The Detector
12
 
  The substances that are passed through a column can be detected by several ways. 
The UV-absorption method is the widely used method of detection. Many organic 
compounds absorb UV light of various wavelengths. The measurement of absorbed UV light 
can be directly determined from the UV detector. The amount of light absorbed is directly 
depend on the amount of particular compound passing through the beam at a specific time. 
 
UV-Visible Detector (Diode Array Detector-DAD)  
 In RP-HPLC method wide variety of detectors like UV-Visible spectrophotometers, 
refractive index detectors (RI), electrochemical detector (EC), evaporative light-
scattering detector (ELS), fluorimeters and others. 
 Due to the presence of grating assembly after the floe cell, the light of different 
wavelength can be measured simultaneously. DADs therefore provide more 
information on sample composition than provided by a single wavelength run. 
 The optimum wavelength for the final HPLC is obtained from the UV spectrum of 
each separated peak. The peak purity can be evaluated from examining the UV 
spectrum from beginning to end. The use of DADs is also important for a peak 
tracking that contain the same compound between different experimental runs during 
method development.
7
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Fig 1: Schematic representation of HPLC 
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HPLC Vs Other Methods
14
 
 The main objective of the pharmaceutical industry is to produce pure drug 
substances which are suitable for the human consumption in a cost effective manner. 
Inorder to check the purity of all pharmaceutical products, the separation methods 
like GC, TLC, HPLC etc are introduced. All these techniques are more sensitive than 
spectroscopic methods.  
 If the compound shows good absorption in between 200-400 nm wavelength, the UV 
method is preferred. In this case, the degraded products or its excipients do not affect 
the absorption. 
 Due to ease of separation, reproducibility and rapid separation, the HPLC method is 
preferred, also HPLC provides higher sensitivity and specificity than the UV method.  
 Since the analyte needs to be neither volatile nor stable at elevated temperature, 
HPLC has an advantage over GC as an analytical technique. 
 Since HPLC is highly accurate and assembled with universal detectors like UV-VIS, 
this makes the quantitation more easily than TLC. 
 Internal and external standard calibration method made it possible to convert for 
structurally dependent differences in detector response.
8
 
 
ANALYTICAL METHOD VALIDATION OF HPLC 
The process of establishing documented evidence is the validation. Validation is an 
assurance that will consistently produce a product meeting its predetermined specifications 
and quality characteristics. 
 
Validation methods are the process that, analytical procedures are suitable for their 
intended use and that they support the identity, potency, quality and purity of the drug 
products. In simple, the analytical method validation is the process of proving that an 
acceptable for its intended purpose. When both the technical and regulatory objectives of the 
analytical methods have been fulfilled, then only a developed method is said to be validated. 
The transfer of a method is best accomplished by a systemic method validation process. The 
primary aim of the validation process is to challenge the method and determine limits of 
allowed variability for the conditions needed to run the method
32,33
. 
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Significance of Method Validation 
   The success of a drug development programme mainly depend on the fact, i.e, the 
quality of the analytical data. The process of method development and validation plays a key 
role in the quality of the datas
34
. 
 
 To trust the method 
 Regulatory requirement. 
 
When we are about to introduce a new product into the market or for the clinical 
trials, analytical method validation is one of the major facts that we has to submit before an 
international regulatory agency. A well developed method can throw out all the potential 
problems and a thoroughly validated method can be used with full confidence for the 
purpose it is proposed. In other words, a through validation can fulfill all the technical and 
regulatory aspects. The development of meaningful specifications can be predicted upon the 
use of validated analytical procedures that can assess changes in a drug substance or drug 
products during its shelf life
35
. 
 
Some of the analytical parameters that are to be validated for a well developed 
method are listed below. Al these parameters may or may not be applicable for all the 
compounds. The selection or validation of the parameters are mainly depend on the purpose 
for which the procedure is required, however, these following aspects of validation should 
be given due to importance. 
 
Accuracy 
The accuracy of an analytical method express the closeness of agreement between 
the value, which is accepted either as a conventional true value or an accepted reference 
value and the value found. 
 
If a method is said to be highly accurate, the measured value of the sample should be 
ideally identical to the true value. The recovery reports should give an idea about the 
accuracy. The usual range of % recovery should be 10 % above or below the expected range 
of claim.  
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The % recovery is calculating using the formula 
 
                        % Recovey =    
100
)(


b
aba
 
                                               
where,  
              a – Amount of drug present in sample 
              b -  Amount of standard added to the sample 
 
Precision 
If the measurement obtained from the multiple sampling of the same homogenous 
sample under same prescribed condition are close, then we say that the method is a precise 
one.  
 
According to ICH guidelines, the precision can be classified into three. 
 Repeatability 
 Intermediate |Precision 
 Reproducibility 
 
Repeatability:  
 It express the precision under the same operating conditions (with-in a short period 
of time, in same laboratory by the same analyst using same equipment) 
 Injection repeatability/Measurement (System Precision) 
 Method repeatability( Method Precison) 
 
Intermediate Precision: 
 Precision should be given under different laboratory condition (with variations in 
laboratory conditions on different days, with different analyst or equipment with-in 
the same laboratory). 
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Reproducibility: 
 Indicates the precision among the laboratories (collaborative studies, usually applied 
to standardization of methodology) 
 
Linearity:  
The linearity may be defined as the ability of the analytical procedure to obtain test 
results, which are directly proportional to the concentration of the sample. 
 
The linearity is determined from 50% of the ICH reporting level to 150% of the 
proposed shelf life specifications of the related substance as a minimum. 
 
Range: 
The linearity of the analytical procedure is its ability to obtain the test results which 
are directly proportional to the concentration of analyte in the sample. It is the upper and 
lower limit of the analyte which we are studied. The concentration interval over which 
acceptable accuracy, precision and linearity were obtained is referred to as the range of an 
analytical procedure. The data secured from the accuracy and precision studies are used to 
determine the range of an analytical method. The linearity studies alone will not give an idea 
about fixing the range of an analytical procedure. 
 
Specificity: 
The ability of the method to accurately measure the analyte response in the presence 
of all potential sample components is the specificity of the developed HPLC method. The 
response of the analyte in test mixtures containing the analyte and all potential sample like 
intermediates, degradants, excipients, impurities etc, is compared with the response of a 
solution containing only the analyte. 
 
There were three methods proposed for the demonstration of specificity. In the first 
method, the HPLC methods were developed, namely, pH, ionic strength, percentage of 
organic solvent, flow rate etc. were changed and observed for the presence of any additional 
peaks. 
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The second method is by using diode array detector to determine the peak purity. 
The diode array spectrum and the diode array first derivative spectrum of the standard and 
sample drug peaks were recorded and compared. 
 
The third method involves the absorbance ratio measurement of the drug peaks at 
two different wavelength. 
 
Limit of Detection (LOD) and limit of Quantification (LOQ) 
The limit of detection of an analytical procedure is defined as the lowest amount of 
analyte in a sample that can be detected, but not quantified. The LOD corresponds to a 
concentration that will give a signal-to-noise ratio of 3:1.  
 
The limit of quantification is defined as the lowest concentration of an analyte in a 
sample that can be determined with acceptable accuracy and precision under the standard 
operational conditions of the method. Limit of quantification is the concentration of related 
substance in the sample that will give a signal-to-noise ratio of 10:1. LOD and LOQ may 
also be calculated from the standard deviation of the response (SD) and the slope of the 
calibration curve (S) at levels approximating the LOD of the formulae.  
 
The LOD and LOQ may be expressed as  
                                         LOD = 3.3 σ/S 
                                         LOQ = 10 σ/S 
 
      Where, σ = the standard deviation of the response 
                  S = the slope of the calibration curve 
 
The slope S may be estimated from the calibration curve of the analyte 
 
Ruggedness:  
Analyzing of the sample under same experimental conditions by different analysts to 
check reproducibility of the method is referred to the ruggedness. This includes different 
analysts, laboratories, columns, instruments, sources of reagents, chemicals, solvents and so 
on
38
. 
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Robustness:  
Robustness is defined as the capacity to remain unaffected by small, but deliberate 
variations in method parameters and provides indication of its reliability during its normal 
usage. Small changes in parameters like mobile phase, pH, buffer concentration, temperature 
and injection volume are made and repeatability is checked. The chromatogram obtained 
with the varied parameters are compared with the chromatogram obtained with the fixed 
conditions
36,37
. 
 
System Suitability: 
The system suitability studies of the methods were performed  by determining 
various chromatographic parameters like column efficiency, resolution, peak asymmetry 
factor, capacity factor, peak area
39
. 
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STRESS DEGRADATION STUDY 
Stability-Indicating Method: 
The stability-indicating method is the quantitative analytical methods that are based 
on the characteristic structural, chemical or biological properties of each ingredient of a 
product and that will distinguish each active ingredient from its degradation product so that 
the active ingredient content can be accurately measured. 
 
The stability indicating method is an analytical method that separates the active 
pharmaceutical ingredient from any degradation (decomposition) products formed under 
defined storage conditions during the stability evaluation period. This method is very much 
essential to detect and quantify one or more degradation products. This analytical method is 
also used for resolving any other potential interfering peaks such as an internal standard. 
Considering all these criteria, the nature of this method indicates the method to be stability-
indicating as well as stability-specific. Stressed testing under forced conditions of oxidation, 
photolysis, hydrolysis and varying pH values may from some decomposition products that 
are unlikely to form under accelerated or long-term stability storage conditions. The 
degraded products may be useful in developing and validating a suitable stability-indicating 
analytical method for the analysis of the drug substances.  
 
Stress testing is defined as the stability testing of the drug substances and the drug 
products under conditions exceeding those used for accelerated testing
40
. 
 
According to ICH guidelines, there are three main purpose for the stress testing
41
. 
1. To provide a stability assessment of the drug substance or the drug product 
2. To elucidate the possible degradation pathways of the drug substance or the active 
pharmaceutical ingredients in the drug product. 
3. To investigate the stability-indicating power of the analytical procedures applied for 
the drug substance and the drug product. 
 
Pharmaceutical companies performs forced degradation studies during pre-
formulation to help select compounds and excipients for further development, to provide 
optimization and produce samples for developing stability-indicating analytical methods. 
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Degradation study provides information about the degradation mechanism and potential 
degradation products. This information can be used to develop manufacturing processes or 
to select proper packaging. It may also help in preparing reference material of identified 
degradation products
42
.  
 
Selected stress testing directly on a drug product may be accepted for the purpose of 
establishment of the validated stability-indicating assay method, if it is proved that no 
physical change occurs in the drug product over the stress period. The stress testing should 
be done on a single batch of the product, which must be of the same composition and the 
quality as the marketing batch, including packaging. The stress tests are normally conducted 
for a period of six months. The samples are observed for physical changes at particular 
intervals. Stress degradation studies are carried out to identify the possible degradation 
products. Stress degradation studies are carried out by solid as well as liquid state using 
different degradation conditions. The container should be chemically inert while performing 
the degradation study and the container for photolysis should be transparent. If the drug 
substance is insoluble in aqueous, acidic or alkaline medium, then the organic solvents can 
be used to dissolve the material. For oxidation purpose a hydrogen peroxide can be used. At 
the end of the exposure period, the samples should be examined for the change of any 
physical properties. Selectivity of the analytical method can be known from the stress 
degradation study. It can be determined from the test results of analysis of test samples with-
out any degradation product
43
. 
 
Factors Affecting Drug Stability: 
 Stability of the API from storage 
 Interaction between the API and the excipients-during Formulation Development 
 Selection of dosage form 
 Manufacturing process of drug product 
 Selection of container closure packaging system 
 Effect of storage 
 Selection of marketing image 
 Handling of finished product 
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ICH Guidelines
41, 44 
: 
The ICH guidelines indicates that stress testing is designed to determine the intrinsic 
stability of the molecule by establishing degradation pathway in order to identify the 
degradation products and to validate the stability indicating power of the analytical 
procedure used. The ICH guidelines stability testing of new drug substances and products 
requires that stress testing should be carried out to reveal the substance. The degradation 
products that are formed under the variety of conditions should include the effect of 
temperature, humidity where appropriate oxidation, photolysis and susceptibility to 
hydrolysis across a wide range of pH value. 
 
Selection of Stress Condition: 
In forced degradation conditions, more severe conditions that accelerated studies are 
used
45
. The stress conditions should be selected such that, it should be consistent with the 
products decomposition under normal manufacturing, storage and use conditions which are 
specific in each case
46
. The choice of forced degradation studies conditions should be based 
on the data from accelerated pharmaceutical studies and sound scientific understanding’s of 
the product decomposition mechanism under typical use conditions. The factors that are 
suggested for the stress degradation study includes acid and base hydrolysis, thermal 
degradation, photolysis, oxidation and may include freeze-thaw cycles and shear
49, 50, 51
. 
 
Degradation product that is produced during the manufacturing and storage should 
be identified, tested and monitored against appropriately established acceptance criteria. The 
forced degradation studies should be designed as a part of the impurity studies. Examination 
of some degradation products formed under stress conditions may not be necessary for 
certain degradants if it has been demonstrated they are not formed under accelerated or long-
term storage conditions. 
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HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY
99
 
The power of thin layer chromatography has been enhanced by considering the 
chromatographic principles to improve the speed and efficiency of separation by 
development of instrumentation to automate sample application, development of 
chromatogram and detection including accurate and precise quantification. As the particle 
size of the layer decreases, the separation will be faster and efficient. The particle size of 
stationary phase has a narrower distribution range with an average size of 5m, instead of 
the average 20m for conventional TLC. The use of mechanical applicators provides 
reproducible application and reduces the diameter of the starting spots. Compared to 
conventional TLC, only very small volume of samples are used in HPTLC, i.e.; about one-
tenth of the sample. The separation time also reduced to the same. In addition to precoated 
silica gel layers, a range of chemically bonded phases, similar to those used in normal- and 
reversed- phase high performance liquid chromatography, are available.  
 
Modern thin layer chromatography can be complementary to HPLC. It allows the 
processing of many samples in parallel, providing low cost analysis of simple mixtures for 
which the sample workload is high. The TLC plates acts as a “Storage detectors” of the 
analyte if they are saved. 
 
IMPORTANT APPLICATION OF PLANAR CHROMATOGRAPHY 
Pharmaceutical industry  
 Quality control  
 Content Uniformity Test  
 Identity/purity checking  
 Phytopharmaceuticals  
  
Food analysis  
 Quality control  
 Additives  
 Pesticides  
 Stability testing  
 Clinical applications  
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 Lipids  
 Metabolic studies  
 Drug screening  
 Stability testing  
Industrial applications  
 Process development and optimization, In-process control  
 Cleaning validation  
Forensic  
 Detection of document false cations, Poisoning investigations  
 Dye stuff analysis  
 Doping control  
Environmental analysis  
 Water  
 Soil  
 Residue analysis  
Sample application
12
 
The samples are applied on to the separation layer, either as spots through capillary 
tube or as narrow bands using the spray-on technique. The criteria like precision of applied 
volume, small size of application zone and exact positioning of sample are essential for the 
quality of the analysis. Band wise sample application as available with Linomat 5 Applicator 
or Automatic TLC Sampler 4 offers the best separation regarding sample solvents and 
application volumes. By using spray-on technique the applied volume can be easily adjusted 
to match the required detection limit of the analytical task. 
 
Chromatogram development 
Chromatogram is developed by capillary force. The developing solvent (mobile 
phase) migrates through the layer (stationary phase) over a defined distance called solvent 
front. During this process the sample is separated into fractions/bands (components). After 
evaporation of the mobile phase by keeping the layer /plate in hot air oven or at room 
temperature, all fractions remain stored on the layer. 
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Derivatization 
It is a special advantage of planar chromatography that fractions are stored on the 
plate and can be derivatized after chromatography. By derivatization, substances that do not 
respond to visible or UV light can be rendered detectable. In case of certain compounds, 
substances or classes of substances can be identified by using specific reagents. 
 
Eg: Ninhydrin, Dragandroffs reagent. 
 
Chromatogram evaluation
20
 
The chromatogram is evaluated under ultraviolet or white light. Options range from 
visual inspection, electronic image processing, video densitometry and documentation to 
quantitative determination by means of monochromatic light in a classical densitometer, 
which additionally facilitates measurement of spectral information. Spectral information’s 
are available through the densitometer. 
 
Two types of ultraviolet light are required for inspecting thin-layer chromatograms: 
 
Long-wave UV light 366nm 
At 366 nm, substances may inherent or reagent induced fluorescence appear as bright 
spots, often differently colored, on a dark background. The sensitivity of this detection 
method is proportional with the intensity of the long-wave UV light and also as more visible 
light is eliminated. A fluorescent indicator F254 contained in the layer neither contributes to 
nor interferes with this detection method.  
 
Short-wave UV light 254nm 
At 254 nm UV substances absorbing at that wavelength become visible, provided the 
TLC layer contains a fluorescent indicator F 254. These substances appear as dark spots on a 
bright background. For this detection method, UV intensity and complete elimination of 
visible light are less critical.  
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 In-House Preparation of TLC Plates 
Only for economic or logistic reason, now a day’s in-house preparation of TLC plates is 
selected. The self-coating of TLC plates should also be considered when special layers are 
required that are not available in the form of precoated plates, e.g. layers containing silver 
nitrate, buffer substances or other reagents, layers consisting of adsorbent mixtures, or in the 
exceptional cases where the binder contained in commercial precoated plates might interfere 
with detection.  
 
Adsorbents for In-House Preparation of TLC Layers 
For the self preparation of chromatographic layers, adsorbents in the form of powder 
are mixed with water or with aqueous solutions of salts or buffer solutions to form thick 
slurry which is spread onto glass plates by means of a coating device. 
 
Adding calcium sulfate as a "binder" makes it easier to achieve the correct 
consistency of the slurry for coating; the calcium sulfate contributes very little to the 
mechanical strength of the layer. 
 
A fluorescence indicator is required to visualize substances which absorb UV light of a 
wavelength (254 nm), by which the indicator is excited to emit visible light. These 
substances appear as dark spots on a bright background. The fluorescence indicator neither 
interferes with the chromatographic separation, with any derivatization reactions, nor with 
densitometric evaluation. On contact with acids, most of these types of indicators lose their 
fluorescence. Only very few precoated layers are available, which with stand its 
fluorescence property against acid.  
 
 Precoated Layers 
The modern planar chromatography utilizes precoated plates. They are more 
convenient and their quality is superior to that of layers available for self-coating. Several 
types of TLC phases, HPTLC layer, etc. are only available in the form of precoated plates. 
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HPTLC Analysis
26
 
High performance thin layer chromatography (HPTLC) is a quality assessment tool 
for the evaluation of a wide variety materials. It allows for the analysis of a broad number of 
compounds both efficiently and cost effectively. In addition to that, numerous samples can 
be run at a single analysis thereby dramatically reducing analytical time. With HPTLC, the 
same analysis can be viewed at different wavelengths of light thereby providing a more 
complete profile of the compound than is typically observed with more specific types of 
analyses. 
 
QUANTITATIVE ANALYSIS
100
 
The primary goal of the method is to provide validated methods to be used for the 
quantitation of the compounds most correlated with pharmacological activity or qualitative 
markers as determined by the primary pharmacological literature, product labeling and a 
survey of experts. The method will be selected from the primary analytical literature by a 
Methods Selection Committee with priority given to compendial methods when available. In 
this context, validation consists minimally of a two-lab validation using the same 
procedures, samples, and reference standards. Primary factors for considering a method as 
appropriate include accuracy of the findings, speed, basic ruggedness, applicability to a large 
segment of the manufacturing community, and avoidance of the use of toxic reagents and 
solvents. In an attempt to promote harmonization, primary consideration is given to those 
methods which are already accepted in official pharmacopoeias or by AOAC International. 
When necessary, comparative tests shall be conducted to determine which of the available 
method(s) is most appropriate. 
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Fig 2: Schematic representation of HPTLC instrument 
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ANALYTICAL METHOD VALIDATION (AMV) FOR HPTLC
6, 103,102
 
The validation of analytical procedures, i.e. the proof of its suitability for the intended 
purpose, is an important part of the registration application for a new drug. The International 
Conference on the Harmonization (ICH) of the Technical Requirements for Registration of 
Pharmaceuticals for Human Use  has harmonized the requirements in two guidelines 
Validation is a process of establishing documented evidence, which provides a high degree of 
assurance that a specific activity will consistently produce a desired result. 
 
Method validation is the process of demonstrating that analytical procedures are 
suitable for their intended use and that they support the identity, quality, purity, and potency 
of the drug substances and drug products. A successful validation guarantees that both the 
technical and regulatory objectives of the analytical methods have been fulfilled. The real 
goal of validation process is to challenge the method and determine limits of allowed 
variability for the conditions needed to run the method
. 
 
1. Specificity  
2. Accuracy (Trueness) 
3. Precision  
 Repeatability  
 Intermediate Precision  
 Reproducibility  
4. Limits of detection and quantitation  
5. Linearity 
6. Range 
7. Robustness 
8. Ruggedness 
9. Stability of analytical solutions 
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STRESS DEGRADATION STUDY 
Stability-Indicating Method: 
40-43
 
The stability-indicating method is the quantitative analytical methods that are based 
on the characteristic structural, chemical or biological properties of each ingredient of a 
product and that will distinguish each active ingredient from its degradation product so that 
the active ingredient content can be accurately measured. 
 
The stability indicating method is an analytical method that separates the active 
pharmaceutical ingredient from any degradation (decomposition) products formed under 
defined storage conditions during the stability evaluation period. This method is very much 
essential to detect and quantify one or more degradation products. This analytical method is 
also used for resolving any other potential interfering peaks such as an internal standard. 
Considering all these criteria, the nature of this method indicates the method to be stability-
indicating as well as stability-specific. Stressed testing under forced conditions of oxidation, 
photolysis, hydrolysis and varying pH values may from some decomposition products that 
are unlikely to form under accelerated or long-term stability storage conditions. The 
degraded products may be useful in developing and validating a suitable stability-indicating 
analytical method for the analysis of the drug substances.  
 
Stress testing is defined as the stability testing of the drug substances and the drug 
products under conditions exceeding those used for accelerated testing. 
 
According to ICH guidelines, there are three main purpose for the stress testing.
45, 46
 
1. To provide a stability assessment of the drug substance or the drug product 
2. To elucidate the possible degradation pathways of the drug substance or the active 
pharmaceutical ingredients in the drug product. 
3. To investigate the stability-indicating power of the analytical procedures applied for 
the drug substance and the drug product. 
 
Pharmaceutical companies performs forced degradation studies during pre-
formulation to help select compounds and excipients for further development, to provide 
optimization and produce samples for developing stability-indicating analytical methods. 
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Degradation study provides information about the degradation mechanism and potential 
degradation products. This information can be used to develop manufacturing processes or 
to select proper packaging. It may also help in preparing reference material of identified 
degradation products.  
 
Selected stress testing directly on a drug product may be accepted for the purpose of 
establishment of the validated stability-indicating assay method, if it is proved that no 
physical change occurs in the drug product over the stress period. The stress testing should 
be done on a single batch of the product, which must be of the same composition and the 
quality as the marketing batch, including packaging. The stress tests are normally conducted 
for a period of six months. The samples are observed for physical changes at particular 
intervals. Stress degradation studies are carried out to identify the possible degradation 
products. Stress degradation studies are carried out by solid as well as liquid state using 
different degradation conditions. The container should be chemically inert while performing 
the degradation study and the container for photolysis should be transparent
45
. If the drug 
substance is insoluble in aqueous, acidic or alkaline medium, then the organic solvents can 
be used to dissolve the material. For oxidation purpose a hydrogen peroxide can be used. At 
the end of the exposure period, the samples should be examined for the change of any 
physical properties. Selectivity of the analytical method can be known from the stress 
degradation study. It can be determined from the test results of analysis of test samples with-
out any degradation product. 
 
ICH Guidelines
41, 44:
  
The ICH guidelines indicates that stress testing is designed to determine the intrinsic 
stability of the molecule by establishing degradation pathway in order to identify the 
degradation products and to validate the stability indicating power of the analytical 
procedure used. The ICH guidelines stability testing of new drug substances and products 
requires that stress testing should be carried out to reveal the substance. The degradation 
products that are formed under the variety of conditions should include the effect of 
temperature, humidity where appropriate oxidation, photolysis and susceptibility to 
hydrolysis across a wide range of pH value. 
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Selection of Stress Condition: 
49, 50, 51
 
In forced degradation conditions, more severe conditions that accelerated studies are 
used. The stress conditions should be selected such that, it should be consistent with the 
products decomposition under normal manufacturing, storage and use conditions which are 
specific in each case. The choice of forced degradation studies conditions should be based 
on the data from accelerated pharmaceutical studies and sound scientific understanding’s of 
the product decomposition mechanism under typical use conditions. The factors that are 
suggested for the stress degradation study includes acid and base hydrolysis, thermal 
degradation, photolysis, oxidation and may include freeze-thaw cycles and shear. 
 
Degradation product that is produced during the manufacturing and storage should 
be identified, tested and monitored against appropriately established acceptance criteria. The 
forced degradation studies should be designed as a part of the impurity studies. Examination 
of some degradation products formed under stress conditions may not be necessary for 
certain degradants if it has been demonstrated they are not formed under accelerated or long-
term storage conditions. 
 
The degradation products can be put into two categories, involving physical 
instability and chemical instability. Chemical instability yields a new chemical molecule 
including modification of the protein. Physical instability denotes the changes in the higher 
order structure. This can lead to denaturation, precipitation and adsorption to surfaces. 
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CHAPTER 2 
LITERATURE REVIEW 
HPLC method  
Mallikarjuna Rao
72
 et al developed a RP-HPLC method for the quantitative determination 
of ZMT. The developed method is also applicable for the related substances determination 
in bulk drugs. The chromatographic separation was achieved on a Waters X Terra RP18 
column. The mobile phase, solution A contained a mixture of phosphate buffer pH 9.85 
methanol: acetonitrile (70:20:10, v/v/v) and solution B contained a mixture of phosphate 
buffer, pH 9.85: acetonitrile (30:70). The detection wavelength was 225 nm. In the 
developed HPLC method, the resolution between ZMT and its potential impurities, namely 
Imp-1, Imp-2 and Imp-3 was found to be greater than 3. The drug was subjected to stress 
conditions of hydrolysis, oxidation, photolysis and thermal degradation. Considerable 
degradation was observed in alkaline medium and oxidative stress conditions. Degradation 
product formed during base hydrolysis was found to be Imp-3.  
 
Mathrusri Annapurna
80
 et al described a simple, precise and accurate RP-HPLC validated 
method for the analysis of ZMT. The separation and quantization were achieved on a 250 
mm reversed phase column with a hydrophilic linkage between silica particles and 
hydrophobic alkyl chains. The mobile phase was constituted of methanol and aqueous tetra 
butyl ammonium hydrogen sulphate, pH 3.4; 10 mM using isocratic elution with, UV 
detection at 224 nm. The method showed good linearity for ZMT in the 1–100 μg mL-1 
range. The limit of quantitation (LOQ) and limit of detection (LOD) were found to be 
0.8134 and 0.2687 μg mL-1 respectively. The applicability of the method was validated 
according to ICH guidelines and can be applicable for the analysis of commercial dosage 
forms. 
 
Xiaoyan Chen
71
 et al described a sensitive and selective liquid chromatography–tandem 
spectrometry method for the determination of ZMT in 0.5 ml of plasma with a linearity 
range of 0.05–30 ng/ml using diphenhydramine as the internal standard. Liquid–liquid 
extraction using a mixture of diethyl ether and dichloromethane was used to extract the drug 
and the internal standard from plasma. The mass spectrometer was operated under the 
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selected reaction monitoring (SRM) mode using the atmospheric pressure chemical 
ionization (APCI) technique. The mobile phase consisted of acetonitrile: water: formic acid 
(70:30:0.5), at a flow rate of 0.5 ml/min. In positive mode, ZMT produced a protonated 
precursor ion at m/z 288 and a corresponding product ion at m/z 58. Internal standard 
produced a protonated precursor ion at m/z 256 and a corresponding product ion at m/z 167. 
The method had a lower limit of quantification of 0.05 ng/ml for ZMT, which offered 
increased sensitivity and selectivity of analysis, compared with existing methods. The 
method was successfully applied to a pharmacokinetic study of ZMT after an oral 
administration of 5 mg ZMT to 20 healthy volunteers. 
 
Srinivasu
73
 et al developed an accurate chiral liquid chromatographic for the enantiomeric 
separation of ZTR-5 [(4S)-4-(4-aminobenzyl) - 2-oxazolidinone, (S)-isomer], a key 
intermediate of ZMT in bulk drugs. The enantiomers of ZTR-5 were baseline resolved on a 
Chiralpak AD-H (250 mm×4.6 mm, 5 μm) column using a mobile phase system containing 
hexane: ethanol (70:30, v/v). The resolution between the enantiomers was not less than four 
and interestingly distomer was eluted prior to eutomer. The limit of detection and limit of 
quantification of (4R)-4-(4-aminobenzyl)-2-oxazolidinone [(R)-isomer] were found to be 
250 and 750 ng/ml, respectively, for 10 µl injection volume. The percentage recovery of 
(R)-isomer ranged from 92.0 to 105.6 in the bulk drug samples of ZTR-5. The validated 
method yielded good results regarding precision, linearity, accuracy and ruggedness. The 
proposed method was found to be suitable and accurate for the quantitative determination of 
(R)-isomer in bulk drug samples of ZTR-5. 
 
Zunjian Zhanla
70
 et al proposed a sensitive and specific liquid chromatography 
electrospray ionization mass spectrometry (LC–ESI–MS) method has been developed and 
validated for the identification and quantification of ZMT in human plasma. After the 
addition of the internal standard and 1 M sodium hydroxide solution, plasma samples were 
extracted with methylene chloride: ethyl acetate mixture (20:80, v/v). The organic layer was 
evaporated under a stream of nitrogen at 40ºC. The residue was reconstituted with 100 µl 
mobile phase. The compounds were separated on a prepacked Lichrospher CN column using 
a mixture of methanol: water (pH 4.0) = 78:22 as mobile phase. Detection was performed on 
a single quadrupole mass spectrometer by selected ion monitoring (SIM) mode via 
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electrospray ionization (ESI) source. The method was proved to be sensitive and specific by 
testing six different plasma batches. Linearity was established for the range of 
concentrations 0.30–16.0 ng/ml with a coefficient of determination (R2) of 0.9998 and good 
back-calculated accuracy and precision. The intra and inter-day precision (RSD. %) were 
lower than 15% and accuracy ranged from 85 to 115%. The lower limit of quantification 
was identifiable and reproducible at 0.30 ng/ml. The proposed method enables the 
unambiguous identification and quantification of ZMT for pharmacokinetic, bioavailability 
or bioequivalence studies. 
 
Vivek Sagar
78
 et al proposed a simple reverse phase HPLC method for the simultaneous 
estimation of Rizatriptan, Sumatriptan and ZMT in bulk form. Chromatography was 
performed by gradient reverse phase separation on a Stainless steel C18 column with mobile 
phase Acetonitrile: Sodium Phosphate buffer. The separation was monitored at 280 nm. The 
retention times were 7.215 min, 8.432 and 9.185 min for of Rizatriptan, Sumatriptan and 
ZMT respectively. The standard curve was linear over a working range of 1–10 μg/ml and 
gave an average correlation coefficient of 0.9996, 0.9992, and 0.9992 for Rizatriptan, 
Sumatriptan and ZMT respectively. The limit of quantitation (LOQ) of this method was 2 
μg/ml for rizatriptan Sumatriptan and ZMT. The absolute recovery was 101.84 for 
rizatriptan, 101.492 for sumatriptan and 101.44 for ZMT. This method can be easily and 
conveniently adopted for routine analysis of Rizatriptan, Sumatriptan and ZMT in pure form 
and can also be used for dissolution or similar studies. 
 
Koti Reddy
77
 et al developed a new sensitive, precise, rapid, specific, and linear and 
stability indicating isocratic HPLC method was developed for the analysis of related 
substances in ZMT. The mobile phase consisted of a mixture of 0.01 M ammonium 
dihydrogen phosphate adjust pH  9.5±0.02 with ammonia solution and acetonitrile in 83:17 
v/v, which was filtered through a 0.22 μ nylon membrane and degassed by sonication before 
use. The chromatographic column used was Waters acquity BEH C18. The column 
temperature was maintained at 40° and the detection wavelength was 225 nm. The potential 
known related substances are impurity-1, impurity-2 and impurity-3. The method can be 
used for the detection and quantification of known and unknown impurities and degradants 
in the drug substance ZMT during routine analysis and also for stability studies in view of 
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its capability to separate degradation products. ZMT was subjected to the stress conditions 
of oxidative, acid, base and photolytic degradation. The degradation product was found to be 
at alkaline hydrolysis and oxidative conditions.  The degradation products were well 
resolved from main peak and its impurities. The method was validated with perfect linearity, 
accuracy, precision, robustness and ruggedness. 
 
Zeynep Aydogmus
76
 et al proposed a simple and sensitive extractive spectrophotometric 
methods for determination of ZMT (ZTP) in tablets. These methods are based on the 
formation of yellow ion-pair complexes between ZTP and tropaeolin OO (TPOO) and 
bromothymol blue (BTB) in citrate–phosphate buffer of pH 4.0 and 6.0, respectively. The 
formed complexes were extracted with dichloromethane and measured at 411.5 and 410 nm 
for TPOO and BTB, respectively. Beer’s law was obeyed in the concentration ranges of 2–
20 and 1.5–17 µg/mL with molar absorptivities of 1.42 X 104 and 1.60 X 104 L/mol/cm for 
the TPOO and BTB methods, respectively. Correlation coefficients were 0.9998 and 0.9999 
for TPOO and BTB methods, respectively. Limits of detection of the TPOO and BTB 
methods were 0.341 and 0.344 µg/Ml , respectively and the limits of quantitation were 1.034 
and 1.051 μg/mL, respectively. Sandell’s sensitivity and stability constant were also 
calculated. The proposed methods have been applied successfully for the analysis of the 
drug in its dosage forms. No interference was observed from excipients present in tablets. 
Statistical comparison of the results with those obtained by a high-performance liquid 
chromatography method showed excellent agreement and indicated nosignificant differences 
in accuracy and precision. 
 
Madhusudhanareddy Induri
79
 et al proposed a simple and rapid RP-HPLC method for 
quantification of ZMT in tablet dosage form. A reversed phase C18 column with dual 
wavelength absorbance detection at 229 nm with a Diode Array Detector was used for the 
study. The mobile phase consisted of acetonitrile and phosphate buffer (pH adjusted to 3.5 
using ortho phosphoric acid) in the ratio of 10:90 % v/v at flow rate of 1.5 mL/min. The 
linearity range was found to be 10-50 μg/mL. The method was validated and it was 
concluded that the developed method was accurate, sensitive, precise, robust and useful for 
the quality control of ZMT in pharmaceutical preparations. 
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Jun Chen
75
 et al developed a simple, rapid and sensitive high-performance liquid 
chromatographic (HPLC) method to quantify ZMT in plasma using an isocratic system with 
fluorescence detection. The method included a single-step liquid–liquid extraction with 
methyl tertiary butyl ether. HPLC separation was carried out by reversed phase 
chromatography with a mobile phase composed of 0.05% (v/v) triethylamine in water 
(adjusting to pH 2.75 with 85% phosphoric acid) and acetonitrile (92:8, v/v). Fluorescence 
detection was performed at 225 nm (excitation) and 360 nm (emission). The calibration 
curve for ZMT was linear from 0.2 to 40 ng/ml. The values of the limit of detection (LOD) 
and limit of quantification (LOQ) were 20 and 40 pg respectively. The method described in 
this report is able to determine low levels of ZMT in human plasma. The detection limit of 
this method for ZMT is 20 pg, which is enough to detect terminal phase concentrations of 
ZMT after oral administration of 5 mg dose of ZMT to healthy volunteers. The validation 
method yielded good results regarding linearity, precision, accuracy, specificity and 
recoveries. In addition, this method has a short chromatographic run (<7 min), so the 
method is more suitable for high-through quantitative analysis such as human 
pharmacokinetic studies. The method was sensitive, simple and repeatable enough to be 
used in pharmacokinetic studies. 
 
Clement
74
 et al proposed that, ZMT, N-desmethyl ZMT, ZMT N-oxide and an internal 
standard (an analogue of ZMT) were extracted from plasma by a solid-phase extraction 
(SPE). Chromatography was performed using isocratic reversed-phase high-performance 
liquid chromatography (HPLC) with coulometric end-point detection. The mobile phase 
consisted of 0.05 M potassium phosphate buffer (pH 3.5) in acetonitrile (87:13, v/v). The 
standard curves were linear over the range 2–20 ng/ml for ZMT and its metabolites in 
plasma. The mean inter- and intra-assay coefficients of variation over the range of the 
standard curves were less than 11%. The absolute recovery averaged 87, 58 and 77% for 
ZMT, N desmethylZMT and ZMT N-oxide, respectively. The assay sensitivity was 0.5 ng 
for each analyte. This method is reasonably cheap to run and can easily be set up I analytical 
as well as clinical laboratory. 
 
Mallikarjuna Rao
72
 et al suggested a gradient, reversed-phase liquid chromatographic (RP-
LC) assay method for the quantitative determination of ZMT. The developed method is also 
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applicable for the related substances determination in bulk drugs. The chromatographic 
separation was achieved on a Waters X Terra RP18 column. The gradient LC method 
employs solutions A and B as mobile phase. The solution A contains a mixture of phosphate 
buffer pH 9.85 methanol: acetonitrile (70:20:10, v/v/v) and solution B contains a mixture of 
phosphate buffer, pH 9.85: acetonitrile (30:70). The detection wavelength was 225 nm. In 
the developed HPLC method, the resolution between ZMT and its potential impurities, 
namely Imp- 1, Imp-2 and Imp-3 was found to be greater than 3. The drug was subjected to 
stress conditions of hydrolysis, oxidation, photolysis and thermal degradation. Considerable 
degradation was found to occur in alkaline medium and oxidative stress conditions. 
Degradation product formed during base hydrolysis was found to be Imp-3. The stress 
samples were assayed against a qualified reference standard and mass balance was found 
close to 99.5%. The developed RP-LC method was validated with respect to linearity, 
accuracy, precision and robustness. 
 
Srinivasua
73
 et al developed a new, accurate and reliable chiral HPLC method was 
developed for the determination of ZMT and its potential impurities namely (4R)-4-[[3-[2-
(dimethylamino)ethyl]- 1H-indol-5-yl] methyl]-2-oxazolidinone [(R)-enantiomer] and (4S)-
4-(4-aminobenzyl)-2-oxazolidinone (Imp-1) in pharmaceutical formulations and in bulk 
drugs. HPLC separation was carried out by normal phase chromatography with a mobile 
phase composed of hexane: isopropanol: methanol: diethylamine in the ratio (75:10:15:0.1, 
v/v/v/v) run on a Chiralpak AD-H column. The presence of diethylamine in the mobile 
phase has played a key role in achieving chromatographic resolution between the 
enantiomers and also in enhancing chromatographic efficiency. The values of the limit of 
detection (LOD) and limit of quantification (LOQ) of (R)-enantiomer and Imp-1 were 100, 
250 ng/ml and 30, 1000 ng/ml, respectively, for 10 µl injection volume. The validated 
method yielded good results regarding selectivity, linearity, precision, accuracy, robustness 
and ruggedness. ZMT sample solution and mobile phase are found to be stable for at least 24 
h. The proposed method was found to be suitable and accurate for the quantitative 
determination of ZMT and its impurities namely (R)-enantiomer and Imp-1 in bulk drugs 
and commercial formulations. 
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 Sasmita Kumari
108
 et al proposed a new method for the determination of ZMT in bulk and 
pharmaceutical formulation by UV, first derivative, and AUC-spectrophotometry. The UV-
spectrophotometry was measured at 283.0 nm in UV spectrophotometry. The linearity 
ranges were found to be 0.5–100 μg/mL in 0.1M HCl and the regression equation was 
A=2.02×10−2C + 4.6×10−4 (R2=0.9999). The response (dA/dλ) of standard solutions was 
measured at 298.0 nm for first derivative method. Calibration curve was constructed by 
plotting dA/dλ values against concentrations, 1–100 μg/mL of ZMT. Regression equation of 
linear calibration graph was calculated as D1= -1.14×10−3C-2.00×10−5 (R2=0.9999). The 
AUC-spectrophotometric method was based on calculation of area under curve (AUC) for 
analysis of ZMT in the wavelength range of 278.0–288.0 nm. Calibration curve was 
constructed by plotting AUC values against concentrations, 0.5–100.0 μg/mL of ZMT. 
Regression equation of linear calibration graph was calculated as 
AUC=1.963×10−1C+1.34×10−3 (R2=0.9999). The methods were validated with ICH 
guidelines. The developed methods were successfully applied to estimate the amount of 
ZMT in pharmaceutical formulations. 
 
Maria Puchalska
109
 et al developed an HPLC method for the analysis of ZMT of 
Pharmaceutical purity. The chromatographic separation was achieved on a Waters XTerra 
RP Column using linear gradient solutions. The mobile phase chosen was 20 mM 
ammonium hydrogen orthophosphate and acetonitrile. In the developed HPLC method, the 
resolution between ZMT and its potential impurities, ZL3, ZL4, ZL5, ZL7, were found to be 
greater than 3. According to ICH guidelines, the obtained product, as pharmaceutical 
substance, should contain less than 0.5% of total impurities and no more than 0.10 % of an 
individual unidentified impurities. The detection limit (0.5 mg mL
-1
) for compoud ZL7 
obtained using the developed HPLC method with spectrophotometric detection is 
unsatisfactory. 
 
Vishwanathan
107
 et al developed a sensitive and selective method for the determination of 
antimigraine drugs from human serum, for understanding the pharmacokinetics of these 
drugs when administered concurrently. The drugs (sumatriptan, naratriptan, ZMT and 
rizatriptan) where extracted with solid phase extraction (SPE) using Oasis HLB .The internal 
standard was bufotenine from serum. A liquid chromatography/tandem mass spectrometry 
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(LC/MS/MS) method was developed and validated for the simultaneous quantification of 
these antimigraine drugs from human serum. The major product ions of the analytes were 
monitored on a triple quadrupole mass spectrometer with positive ion electrospray ionization 
(ESI) with multiple reaction monitoring (MRM) mode. The base peak in all the analytes is 
formed by alpha cleavage associated with protonation of the secondary amine. Mechanisms 
for the formation of the collision-induced dissociation products of these antimigraine 
compounds are proposed. The calibration curves were obtained with 1-100 ng/mL and it was 
linear with all coefficients of determination greater than 0.99. The inter- and intraday 
precision (%RSD) were less than 9.3% and accuracy (%error) was less than 9.8% for all 
components. The limits of detection (LOD) for the method were 250 pg/mL for sumatriptan 
and 100 pg/mL for the remaining analytes based on a signal-to-noise ratio of 3. 
 
Yao Jin-cheng
105
 et al established a new rapid and sensitive HPLC-MS method for the 
determination of ZMT in human plasma and they extended this study to determine the 
pharmacokinetics of ZMT in healthy volunteers.  A single oral dose of 5 mg of ZMT tablet 
was given to 20 healthy male volunteers. After the administration, blood samples were 
collected for a period of 24 h, and the concentration of drug in plasma was analyzed by 
HPLC-MS.  The plasma concentration-time course fitted well a two-compartment open 
model with a lag time, giving the following pharmacokinetic parameters: Tmax 1.60±0.24 
h, Cmax 9.73±1.43 ng·mL
-1
, T1/2α1.72±0.46 h, T1/2β4.52±0.97 h and AUC0-t 55.59±5.12 
ng·mL
-1
·h. The improved analytical method for ZMT is rapid, sensitive and suitable for 
application to pharmacokinetic studies and routine determination of numerous samples. 
 
Hu YZ
106
 et al developed an analytical method and quality control for the determination of 
ZMT and related substances. ZMT and related substances were separated on a shimadzu 
CLC-C (8) column (150 mm x 6 mm, 10 micron). Acetonitrile-10 mmol/L and phosphate 
buffer pH 7.5 in the ratio 25:75 was optimized as the mobile phase and a flow-rate of 1 
ml/min; was kept. The detection wave length was found to be at 229 nm. The limit of 
detection for the related substances was 0.5 ng on the ZMT basis (S/N >3). The calibration 
curve was drawn from 4 - 40 mcg/ml. The correlation coefficient was found at 0.9999. The 
recovery rate of ZMT was 99.1% with a standard deviation of 0.2%. The results of HPLC 
method were consistent with those of non-aqueous titration method. The developed HPLC 
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method is rapid sensitive and accurate method for the determination of ZMT and its related 
substances. 
 
Vijayakumar
104
 et al proposed a new stability indicating, precise, specific, linear isocratic 
HPLC method for the analysis of related substances in ZMT. The potential known related 
substances are (S)-4-(4-aminobenzyl)-1, 3-oxazolidin-2-one (impurity 1) and (S)-4-(4-
hydrazinobenzyl)-1, 3-oxazolidin-2-one (impurity 11). This method can be used for the 
quantition and detection of both known and unknown impurities as well as for the stability 
studies and for the identification of degradation products. The forced degradation method 
was developed to establish the stability of this method. The detection wave length was fixed 
at 225 nm. The mobile phase consisted of a mixture of 0.02M ammonium formate 
containing 0.1% n-propylamine and acetonitrile in 80:20 v/v. The retention time of ZMT, 
impurity 1 and 11 are found to be at 11.0, 4.7, 27.6 mins respectively with a resolution of 
13.5 between ZMT and impurity 1 and 24.1between ZMT and impurity 11. The degradation 
was found under the alkaline hydrolysis and oxidative conditions. 
 
HPTLC Method  
Himani Agrawal
95
et al developed a sensitive, accurate, precise and stability indicating 
high-performance thin layer chromatographic method of analysis of clopidogrel bisulphate 
both as a bulk drug and in formulations was developed. The method employed TLC 
aluminium plates precoated with silica gel 60F-254 as the stationary phase. The solvent 
system consisted of carbon tetrachloride: chloroform: acetone (6:4:0.15, v/v/v). This system 
was found to give compact spots for clopidogrel bisulphate with Rf value of 0.309. 
Clopidogrel bisulphate was subjected to acid and alkali hydrolysis, oxidation, photo 
degradation and dry heat treatment. Also the degraded products were well separated from 
the pure drug. The detection wavelength was 230 nm. The linear regression data for the 
calibration plots showed good linear relationship with R
2
 0.9999/in the concentration range 
of 200_/1000 ng. The method was validated according to ICH guidelines. The drug 
undergoes degradation under acidic and basic conditions, oxidation and dry heat treatment. 
All the peaks of degraded product were resolved from the standard drug with significantly 
different Rf values.  
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Ansari
94
 et al proposed a simple, selective, precise and stability-indicating high-
performance thin-layer chromatographic method of analysis of curcumin both as a bulk drug 
and in formulations was developed and validated. The method employed TLC aluminium 
plates precoated with silica gel 60F- 254 as the stationary phase. The solvent system 
consisted of chloroform: methanol (9.25:0.75 v/v). Rf value was found at 0.48. The 
detection wavelength was fixed at 430 nm. The linear regression analysis data for the 
calibration plots showed good linear relationship with R
2
 = 0.996 and 0.994 with respect to 
peak height and peak area, respectively, in the concentration range 50–300 ng per spot. The 
method was validated for precision, recovery and robustness. Curcumin was subjected to 
acid and alkali hydrolysis, oxidation and photo degradation. The drug undergoes degradation 
under acidic, basic, light and oxidation conditions.  
  
Kotiyan
93
 et al developed a rapid, selective and precise stability indicating high 
performance thin layer chromatography method was developed and validated for the 
estimation of ESD in bulk and pharmaceutical dosage forms. The method employed TLC 
aluminium plate precoated with silica gel 60F254 as the stationary phase. The solvent 
system employed consisted of chloroform–acetone–isopropyl alcohol–glacial acetic acid 
(9:1:0.4:0.1, v: v: v: v). Rf value was found to be at 0.409. The drug on intentional 
degradation gave two products with Rf values of 0.5290 and 0.5890 respectively. 
Spectrodensitometric scanning-integration was performed on a Camag system using a 
wavelength of 286 nm. The polynomial regression data for the calibration plots exhibited 
good linear relationship (R
2
=0.9947) over a concentration range of 1–8 mg. The proposed 
method was found to be stability indicating. Statistical analysis proves that the method is 
precise, accurate and reproducible, hence can be employed for the routine analysis of the 
drug.  
 
Kohli
110 
et al introduced a simple, sensitive, selective, and precise and stability indicating 
high-performance thin-layer chromatographic method for determination of gatifloxacin both 
as a bulk drug and from polymeric nanoparticles was developed and validated as per the 
International Conference on Harmonization (ICH) guidelines. The method employed thin-
layer chromatography (TLC) aluminium plates precoated with silica gel 60F-254 as the 
stationary phase and the mobile phase consisted of n-propanol: methanol: concentrated 
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ammonia solution (25%) (5:1:0.9, v/v/v). This solvent system was found to give compact 
spots for gatifloxacin Rf value of 0.6. Densitometric analysis of gatifloxacin was carried out 
in the absorbance mode at 292 nm. The linear regression analysis data for the calibration 
plots showed good linear relationship with R
2
 = 0.9953 with respect to peak area in the 
concentration range of 400–1200 ng/spot. The mean value (±S.D.) of slope and intercept 
were 9.66±0.05 and 956.33±27.67, respectively. Gatifloxacin was subjected to acid and 
alkali hydrolysis, oxidation, photo degradation and dry heat treatment. The drug undergoes 
degradation under acidic and basic conditions and upon wet and dry heat treatment. The 
degraded products were well separated from the pure drug. As the method could effectively 
separate the drug from its degradation products, it can be employed as stability-indicating 
one. 
 
Vader
90
 et al proposed a simple, selective, precise and stability-indicating high-performance 
thin-layer chromatographic method of analysis of imatinib mesylate both as a bulk drug and 
in formulations. The method employed HPTLC aluminium plates precoated with silica gel 
60F-254 as the stationary phase. The solvent system consisted of chloroform: methanol (6:4, 
v/v). Rf value was fixed at 0.53.Densitometric analysis of imatinib mesylate was carried out 
in the absorbance mode at 276 nm. The linear regression analysis data for the calibration 
plots showed good linear relationship with R
2
 = 0.9966±0.0013 with respect to peak area in 
the concentration range 100–1000 ng per spot. The method was validated for precision, 
recovery and robustness. Imatinib mesylate was subjected to acid and alkali hydrolysis, 
oxidation and thermal degradation. The drug undergoes degradation under acidic, basic, 
oxidation and heat conditions. This indicates that the drug is susceptible to acid, base 
hydrolysis, oxidation and heat. The proposed developed HPTLC method can be applied for 
identification and quantitative determination of imatinib mesylate in bulk drug and dosage 
forms. 
 
Neeraj Kaul
89
 et al developed a sensitive, selective, precise and stability-indicating high-
performance thin layer chromatography (HPTLC) method for analysis of indinavir sulphate 
both as a bulk drug and in formulations was developed and validated. The method employed 
TLC aluminium plates precoated with silica gel 60F-254 as the stationary phase. The solvent 
system consisted of carbon tetrachloride/chloroform/methanol/10% v/v ammonia 
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(4:4.5:1.5:0.05, v/v/v/v). The wavelength was fixed at 260 nm. Rf value was found at 0.63.  
Indinavir sulphate was subjected to acid and alkali hydrolysis, oxidation, dry and wet heat 
treatment, and photo degradation. The drug undergoes degradation under acidic and basic 
conditions, oxidation, dry and wet heat treatment, and photo degradation. Also the degraded 
products were well resolved from the pure drug with significantly different Rf values. The 
method was validated for linearity, precision, robustness, limit of detection (LOD), limit of 
quantitation (LOQ), specificity and accuracy. Linearity was found to be in the range of 100–
6000 ng/spot. As the method could effectively separate the drug from its degradation 
products, it can be employed as a stability-indicating one.  
 
Nilu Jain
88
 developed a simple, stability-indicating high-performance thin-layer liquid 
chromatographic (HPTLC) method for analysis of minocycline was developed and 
validated. The densitometric analysis was carried out at 345 nm. The mobile phase was 
fixed as methanol: acetonitrile: isopropyl alcohol: water (5:4:0.5:0.5, v/v/v/v). The method 
employed TLC aluminium plates pre-coated with silica gel 60F-254 as the stationary phase. 
To achieve good result, plates were sprayed with a 10% (w/v) solution of disodium ethylene 
diamine tetra acetic acid (EDTA), the pH of which was adjusted to 9.0. Compact spots of 
minocycline were found at Rf = 0.30±0.02. The correlation coefficient, R
2
 = 0.9997. The 
drug undergoes acidic and basic degradation, oxidation and photo degradation. All the peaks 
of degradation products were well resolved from the pure drug with significantly different 
Rf values. The acidic and alkaline degradation kinetics of minocycline, evaluated using this 
method, is found to be of first order. 
 
Sanjay K. Motwani
87 
et al proposed simple, sensitive, selective, precise and stability-
indicating HPTLC method for densitometric determination of moxifloxacin both as a bulk 
drug and from pharmaceutical formulation. The method employed TLC aluminium plates 
pre-coated with silica gel 60F-254 as the stationary  phase and the mobile phase consisted of 
n-propanol–ethanol–6M ammonia solution (4:1:2, v/v/v). Densitometric analysis of 
moxifloxacin was carried out in the absorbance mode at 298 nm. Compact spots for 
moxifloxacin were found at Rf value of 0.58±0.02. The linear regression analysis data for 
the calibration plots showed good linear relationship with R
2
 = 0.9925 in the working 
concentration range of 100–800 ng spot−1. The method was validated for precision, 
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accuracy, ruggedness, robustness, specificity, recovery, LOD and LOQ. Drug was subjected 
to acid and alkali hydrolysis, oxidation, dry heat, wet heat treatment and photo degradation. 
All the peaks of degradation products were well resolved from the standard drug with 
significantly different Rf values. As the method could effectively separate the drug from its 
degradation products, it can be employed as stability-indicating one. Moreover, the proposed 
HPTLC method was utilized to investigate the kinetics of the acidic and alkaline degradation 
processes at different temperatures.  
 
Neeraj Kaul
86
 et al developed a sensitive, selective, precise and stability indicating 
HPTLC method of analysis of nelfinavir mesylate both as a bulk drug and in formulations. 
The method employed TLC aluminium plates precoated with silica gel 60F-254 as the 
stationary phase. The solvent system consisted of toluene:methanol:acetone (7:1.5:1.5, 
v/v/v). This system was found to give compact spots for nelfinavir mesylate (Rf value of 
0.45±0.02). Nelfinavir mesylate was subjected to acid and alkali hydrolysis, oxidation, dry 
heat treatment and photo degradation.  The wavelength was fixed at 250 nm. The linear 
regression analysis data for the calibration plots showed good linear relationship with 
R
2
=0.999±0.002 in the concentration range of 1000–6000 ng per spot. The method was 
validated for precision, robustness and recovery. As the method could effectively separate 
the drug from its degradation products, it can be employed as a stability indicating one. 
 
Neeraj Kaul
97
 et al proposed a precise, sensitive, selective and stability-indicating high-
performance thin-layer chromatographic method for the  analysis of nevirapine both as  a 
bulk drug and in formulations was developed and validated. The mobile phase consisted of 
toluene–carbon tetrachloride–methanol–acetone–ammonia (3.5:3.5:2.0:1.0:0.05, v/v/v/v/v). 
Absorbance mode was fixed at 289 nm. Rf value of nevirapine was found at 0.44 ± 0.02. 
Nevirapine was subjected to acid and alkali hydrolysis, oxidation, dry heat and wet heat 
treatment and photodegradation. The drug undergoes degradation under acidic, basic 
conditions and oxidation. Also the degraded products were well resolved from the pure drug 
with significantly different Rf values. Linearity was found to be in the range of 30–1000 
ng/spot with good value of correlation coefficient. The linear regression analysis data for the 
calibration plots showed good linear relationship with R
2 
= 0.998 ± 0.002.  The method was 
validated for precision, robustness and recovery. The LOD and LOQ were 5 and 10 ng/spot 
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respectively. As the method could effectively separate the drug from its degradation 
products, it can be employed as a stability indicating one.  
 
Puthli
85
 et al suggested a rapid and sensitive HPTLC method was developed and validated 
for the estimation of Piroxicam. The wavelength was fixed at 360 nm. To justify the 
suitability, accuracy and precision of the proposed method, recovery studies were performed 
at three concentration levels. One of the degradation products of piroxicam is 2-
aminopyridine (2AP). A TLC aluminium plate precoated with silica gel 60F-254 was used 
as the stationary phase. The solvent system consisted of toluene–acetic acid (8:2 v:v),which 
gave a compact spot of piroxicam with a Rf value of 0.5890.01 which was well separated 
from 2AP (Rf 0.2390.01). The calibration plots exhibited good linear relationship coefficient 
of correlation R
2
=0.9982 over a concentration range of 400–800 ng. Statistical analysis 
proves that the proposed method is accurate and reproducible. The method is stability 
indicating and being economical can be employed for the routine analysis in bulk drug as 
well as pharmaceutical formulations.  
 
Sapna
84
 et al developed rapid, selective and stability indicating high performance thin layer 
chromatographic method was developed and validated for their simultaneous estimation in 
pharmaceutical dosage forms. The method employed TLC aluminium plates precoated with 
silica gel 60F-254 as the stationary phase and solvent system consisted of ethyl acetate–
methanol– ammonia (7:1.5:1, v/v/v). This system was found to give compact spots for both 
pseudoephedrine (Rf value of 0.69_0.01) and cetirizine (Rf value of 0.38_0.01). The 
detection wavelength was fixed at 240 nm. The calibration plots showed good linear 
relationship with R
2
=0.9947 in the concentration range of 10–26 ng for pseudeophedrine and 
200–1200 ng for cetirizine with R2=0.9973. The method was validated for precision, 
accuracy, ruggedness and recovery. Both the drugs do not undergo degradation under acidic 
and basic conditions. The samples degraded with hydrogen peroxide showed additional 
peaks at Rf values of 0.75 and 0.28 for pseudoephedrine and cetirizine, respectively. This 
indicates that both the drugs are susceptible to oxidation. Statistical analysis proves that the 
method is reproducible and selective for the simultaneous estimation of pseudoephedrine 
and cetirizine. As the method could effectively separate the drugs from their degradation 
products, it can be employed as a stability indicating one. 
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Sanjivani
83
 et al proposd a simple, rapid ,selective and sensitive HPTLC method for the 
estimation of timolol in bulk drug and formulations. The mobile phase selected was ethyl 
acetate–methanol–isopropyl alcohol–ammonia (25%) (80:20:2:1, v:v:v:v). The calibration 
curve of the drug was linear in the range of 100–600 ng. The spectrodensitometric analysis 
was carried out at 294 nm. The system precision and the method precision were excellent 
with an RSD of 2.8 and 1.004, respectively. The limits of detection and quantitation were 10 
and 40 ng, respectively. The mean percent recovery was found to be 98.6. Timolol maleate 
was degraded by exposing the drug to heat, acid and base. The degraded products were 
found to be well separated from the pure drug with significantly different Rf values. The 
reported method is simple, selective, precise, accurate, time saving and economic as 
compared to reported HPLC methods. Hence this method can be employed as a stability 
indicating analysis method for quantification of timolol maleate in pharmaceutical 
preparations and as bulk drug. 
 
Mahadik
82
 et al suggested a simple, selective, precise and stability-indicating high-
performance thin-layer chromatographic method of analysis of tizanidine hydrochloride both 
as a bulk drug and in formulations.The method employed TLC aluminium plates precoated 
with silica gel 60F-254 as the stationary phase. The solvent system consisted of 
toluene:/acetone:ammonia (5:5:0.1, v/v/v). The Rf value of tizanidine was found at 
0.329/0.01). Tizanidine hydrochloride was subjected to acid and alkali hydrolysis, oxidation 
and photodegradation. Also, the degraded product was well separated from the pure drug. 
Densitometric analysis of tizanidine hydrochloride was carried out in the absorbance mode 
at 315 nm. The linear regression analysis data for the calibration plots showed good linear 
relationship with R
2
=0.9922 in the concentration range 300 -/1000 ng per spot. The method 
was validated for precision, recovery and robustness. The limits of detection and 
quantitation were 88 and 265 ng per spot, respectively. The samples degraded with hydrogen 
peroxide showed additional peak at Rf value of 0.12. This indicates that the drug is 
susceptible to oxidation. Statistical analysis proves that the method is repeatable and 
selective for the estimation of tizanidine. As the method could effectively separate the drug 
from its degradation product, it can be employed as a stability-indicating one. 
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Simmy
81
 et al proposed a simple,precise and stability-indicating high-performance thin-
layer chromatographic method of estimation of trimetazidine hydrochloride both as a bulk 
drug and in formulations. The mobile phase composition was n-butanol-water-methanol-
ammonia (20%) (14:0.2:0.2:2, v:v:v:v). Densitometric detection of trimetazidine 
hydrochloride was carried out in the absorbance mode at a wavelength of 254 nm. The 
calibration curve of trimetazidine hydrochloride in methanol was linear in the range 400 – 
2400 ng. The mean value of correlation coefficient was 0.99815,which shows a good 
correlation. The limits of detection and quantitation were 50 and 80 ng respectively. The 
recovery of trimetazidine hydrochloride was about 98 – 100%. The drug was subjected to 
different degradation conditions and the degraded products could be easily separated from 
the drug. Hence this developed method can be employed as a stability indicating one. 
 
Ibrahim
111
 et al developed a validated sensitive and highly selective stability indicating 
methods are adopted for simultaneous quantitative determination of sulpiride and 
mebeverine hydrochloride in presence of their reported impurities and hydrolytic degradates 
whether in pure forms or in pharmaceutical formulation. The first method is High 
Performance Liquid Chromatography, where the mixture of sulpiride and mebeverine 
hydrochloride together with metopimazine as internal standard are separated on a reversed 
phase cyano column (5 mm ps, 250 mm X4.6 id) using acetonitrile: water (70:30 v/v) 
adjusted to pH ¼ 7 as a mobile phase. The detection wavelength was fixed at 221 nm over a 
concentration range of 5-40 mg m-
l
 and 5-60 mg ml
1
 with mean percentage recoveries 
99.75% and 99.99% for sulpiride and mebeverine hydrochloride respectively. The second 
method is High Performance Thin Layer Chromatography, where sulpiride and mebeverine 
hydrochloride are separated on silica gel HPTLC F254 plates using absolute 
ethanol:methylene chloride: triethyl amine (7:3:0.2 by volume) as mobile phase and 
scanning of the separated bands at 221 nm over a concentration range of 0.4-1.4 and 0.2-1.6 
mg band
-1
with mean percentage recoveries 101.01%  and 100.40% for sulpiride and 
mebeverine hydrochloride respectively. 
 
Neeraj kaul
97
 et al proposed a precise, sensitive, selective and stability-indicating high-
performance thin-layer chromatographic method of analysis of nevirapine both as a bulk 
drug and in formulations was developed and validated. The mobile phase consisted of 
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toluene–carbon tetrachloride–methanol–acetone–ammonia (3.5:3.5:2.0:1.0:0.05,v/v/v/v/v). 
Densitometric analysis of nevirapine was carried out in the absorbance mode at 289 nm. 
This system was found to give compact spots for nevirapine at Rf value of 0.44 ± 0.02. 
Nevirapine was subjected to acid and alkali hydrolysis, oxidation, dry heat and wet heat 
treatment and photodegradation. The drug undergoes degradation under acidic, basic 
conditions and oxidation. The degraded products were well resolved from the pure drug with 
significantly different Rf values. Linearity was found to be in the range of 30–1000 ng/spot 
with significantly high value of correlation coefficient of R
2
 = 0.998 in the working 
concentration range of 300 ng/spot to 1000 ng/spot. The method was validated for precision, 
robustness and recovery. The limit of detection and quantitation were 5 and 10 ng/spot, 
respectively. As the method could effectively separate the drug from its degradation 
products, it can be employed as a stability indicating one.  
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CHAPTER III 
DRUG PROFILE  
 
 Drug Name  :       Zolmitriptan 
 Molecular formulae :       C16 H21N3O2 
 Molecular weight     :       287.36 
                                                    
                                    Fig:3  Chemical structure of ZMT 
 
 Chemical name  :  4(S)-4-[3-(2-dimethyl aminoethyl)-1H-5- indolyl- 
methyl]-1,3- oxazolan-2-one 
 
 Color and nature : White to almost powder 
 
 Solubility  :         Freely Soluble in methanol, soluble in ethanol,  
Sparingly soluble in Dichloromethane and insoluble in     
  water 
 
 Melting point  : 136 - 141ºC 
 
 Category  : ZMT is a selective serotonine 5-HT 
                                              receptor agonist 
Used for the treatment of migrane. 
 Dosage Forms  : Available as, 
                           Tablet 2.5 and 5.0 mg 
                                                Orally disintegrating tablet 2.5 and 5.0 mg. 
                                                Nasal spray 5.0 mg.  
           
 Half life  : 2-3 hours 
Drug Profile 
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Chemistry and pharmacology: 
ZMT is a selective 5HT1D and 5HT1B receptor drug. It is converted to an active                
N-desmethyl metabolite which has several fold higher affinity for 5HT1D and 5HT1B   
receptors than the parent drug. Two hypothesis have been proposed to explain the efficacy 
of the drug in migrane therapy. One hypothesis implicates the ability of receptors to cause 
the constriction of intracranial blood vessels including arteriovenous anastomoses and thus 
restore the blood flow to the brain. Second hypothesis relates to the observation that both 
5HT1D and 5HT1B receptors serve as presynaptic autoreceptors, modulating neurotransmitter 
relief from neuronal terminal. ZMT may block the release of proinflammatory neuropeptides 
at the level of nerve terminal in the perivascular space. 
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CHAPTER IV 
AIM AND OBJECTIVE OF THE WORK 
 
 ZMT is a synthetic triptamine derivative, chemically known as (s)-4-{[3-(2-
dimethylaminoethyl)-1H-indol-5-yl] methyl} 1, 3-oxazolidin-2one. It is an oral, 
selective serotonin receptor agonist of the serotonin receptor and is used for the 
treatment of acute migraine attacks. It causes constriction of the blood vessels there 
by relieving the pain due to migraine headache. 
 
 It is a Non-Pharmacopoeial drug. 
 
 Several analytical HPLC methods were reported in literature for the quantitative 
determination of ZMT and its metabolites in human plasma and other biological 
fluids.  
 
 Very few achiral and chiral HPLC methods were reported for the detection and 
quantification of the related impurities and degradation products in the drug substance 
ZMT. 
 
 Since there is no HPTLC method reported for the stress degradation studies of this 
drug and some of the reported HPLC stress-degradation methods presented 
unsatisfactory peak symmetry, it was proposed to develop, validate and perform 
forced degradation studies for the determination and quantification of degradation 
products of ZMT by HPLC and HPTLC methods. 
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CHAPTER V 
PLAN OF WORK 
HPLC & HPTLC 
 Selection of suitable method for the study  
 Selection of suitable wavelength 
 Method development 
 Selection of suitable mobile phase 
 Quantification of drugs by selected method 
 Validation of RP-HPLC and HPTLC method 
 Accuracy 
 Precision 
 Linearity 
 Robustness 
 Ruggedness 
 Solution stability 
 Limit of detection (LOD) 
 Limit of quantification (LOQ) 
 Stress degradation studies 
 Determination of degradants 
STRESS DEGRADATION STUDY 
1. Liquid state degradation study 
 Neutral hydrolysis 
 Acid hydrolysis 
 Base hydrolysis  
 Oxidation  
 Photolysis 
2. Solid state degradation study 
 Dry heat degradation study (120° C) 
Experimental 
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CHAPTER VI 
EXPERIMENTAL 
 
HIGH PRESSURE LIQUID CHROMATOGRAPHY (HPLC) 
METHOD DEVELOPMENT AND OPTIMIZATION 
 
Method Development 
Bulk drug:          ZMT supplied by Orchid Health Care Chennai 
Chemicals and Solvents:  
 HPLC grade Acetonitrile 
 HPLC grade Methanol 
 Analytical reagent grade sodium hydroxide 
 Analytical reagent grade hydrochloric acid 
 Analytical reagent grade hydrogen peroxide 
 Ortho phosphoric acid 
 HPLC grade water was prepared by using Millipore MilliQ water purification 
system. 
Instruments: 
 HPLC  : Shimadzu Prominance 
 Detector : SPD-M20A Prominance-diode array detector 
 Pump  : LC-20AT Prominance –liquid chromatogram (Rheodyne  
7725i with 20µL loop injector. The output signal was 
monitored and processed using LC Solution software on HCL 
computer). 
 Sonica ultrasonic cleaner sonicator was used 
 pH meter (Elico LI 127) 
 Hot air oven was used for thermal stability studies. 
 
  
Experimental 
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OPTIMIZATION 
Selection of wavelength  
The wave length for the analysis of ZMT was selected from the UV spectrum 
absorbance of ZMT by scanning in the range of 200-400nm. From this spectrum, the 
wavelength of 226 nm was selected for the final method since the drug has shown good 
absorbance.  
 
Selection of mode of separation 
The selection of the method depends on the nature of the sample, its molecular 
weight and solubility. The drug selected for the present study is polar in nature and hence 
RP-HPLC method was preferred because of its simplicity and suitability. 
 
Initial chromatographic conditions 
Trial 1 
Stationary phase : C-18 column 
Mobile phase  : 70:30 
Aqueous phase : Water (pH 3.0) 
Organic phase  :  Acetonitrile 
Detection wavelength : 226 nm 
Flow rate  : 1 ml/min 
Temperature  : Room temperature of 25 ±2º c 
 
Trial 2 
Stationary phase : C-18 coumn 
Mobile phase  :  80:20 
Aqueous phase : phosphate buffer (pH 3.0) 
Organic phase  : Acetonitrile:Methanol (50:50) 
Detection wave length:  226 nm 
Flow rate  :  1 ml/min 
Temperature  :  Room temperature of 25±2ºc 
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Effect of pH: 
With the initial chromatographic conditions, the standard solution were 
chromatographed for 20 min using 30% acetonitrile in water with pH ranging from 2.5 to 
4.5 at 1 ml/min flow rate. There was found no significant change in retention time. Then the 
standard solution was chromatographed with 50:50 ratio of acetonitrile and methanol as 
organic solvent of different pH from 3.0 to 4.0 at the same flow rate of 1 ml/min. It was 
observed that the increase in pH decreases the retention time. For the present study, pH 3.5 
was selected. 
 
Effect of flow rate: 
The flow rate shall be selected depends on the following data ; 
 Retention time 
 Peak symmetry 
 Column back pressure 
Preferably the flow rate shall not be more than 2.5 ml/min. the selection of flow rate 
was done as flow rate which gives the least retention time and good peak symmetry. 
 
Fixed chromatographic conditions 
Stationary phase  : C-18 column 
Mobile phase   : Solvent A (Phosphate buffer, pH 3.5) 
: Solvent B (Acetonitrile: Methanol, 50:50) 
pH    : 3.5 (adjusted with Orthophosphoric acid) 
Solvent ratio   : 85 : 15 
Detection wavelength  : 226 nm 
Flow rate   : 1 ml/min 
Temperature   : Room temperature of 25±2ºC 
Injection volume  : 20 µL 
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VALIDATION OF THE METHOD 
System suitability 
System suitability of method was performed by calculating the chromatographic 
parameters namely, column efficiency, resolution, peak symmetry factor and capacity factor 
on the repetitive of injection of standard solution. 
 
Linearity and Range 
A stock solution of the drug was prepared at a strength of 1 mg/ml. it was diluted to 
prepare solution containing 2-10 µg/ml in bulk sample of ZMT; the percentage of recoveries 
were calculated. 
 
Precision 
The precision of the developed method was determined in terms of intermediate 
precision (intra-day and inter-day). Three different concentrations of ZMT were analyzed in 
six independent series during the same day(intra-day precision) and six consecutive days 
(inter-day precision); with each series every sample was injected in triplicate. The %RSD 
values of intra-day and inter-day studies for ZMT showed that the precision of the method 
was satisfactory. 
 
 Specificity and Selectivity 
The specificity of the method was established through study of resolution factors of 
the drug peak from the nearest resolving peak, and also among all other peaks. 
 
Limit of Detection (LOD) and limit of Quantification (LOQ) 
LOD is the smallest concentration of the analyte that can be detected and gives the 
measurable response (signal to noise ratio of 3). The signal to noise ratio were performed by 
comparing by measured signal of known low concentration of drug. LOQ is the smallest 
concentration of the analyte that can be accurately quantified (signal to noise ratio 10). 
 
Solution stability 
The solution stability of ZMT was carried out by leaving the test solution in a tightly 
capped volumetric flask at room temperature for 48 hours. The same sample solution was 
assayed for 24hr interval up to a study period against freshly prepared solution of ZMT. The 
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%RSD of assay of ZMT was calculated for the subject period during solution stability 
experiments. 
 
Ruggedness and Robustness of the method 
The ruggedness and robustness of the methods were determined by analyzing the 
sample at normal operating conditions and also by changing some operating analytical 
conditions such as column make, mobile phase compositions, flow rate, instrument and 
analyst. 
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STRESS DEGRADATION STUDY 
 
Types of stress degradation study: 
1. Liquid state degradation study 
2. Solid state degradation study 
 
Liquid state degradation study:  
1. Base hydrolysis ( 0.1 M NaOH) 
2. Acid hydrolysis (0.1M and 1M HCl) 
3. Oxidation (3% H2O2) 
4. Photolysis 
 
Liquid state degradation study 
Acid hydrolysis: 
Ten ml of the 10 µg/ml of sample solution was transferred to a round bottomed flask 
and then 10 ml of the 0.1 M and 1 M HCl was added to the above and refluxed for 8 h in a 
boiling water bath. At the end of the exposure, the solution was cooled and neutralized with 
10 ml NaOH.  
 
Base hydrolysis: 
Ten ml of the 10 µg/ml of sample solution was transferred to a round bottomed flask 
and then 10 ml of the 0.1 M NaOH was added to the above and refluxed for 8 h in a boiling 
water bath. At the end of the exposure, the solution was cooled and neutralized with 10 ml 
HCl.  
 
Oxidation: 
Ten ml of the 10 µg/ml of sample solution was transferred to a round bottomed flask 
and then 10 ml of 3% H2O2 was added to the above and refluxed for 8 h in a boiling water 
bath. At the end of the exposure, the solution was cooled.  
 
Photolysis: 
Fifty ml of 10 µg/ml of the sample solution was taken in a standard flask and kept at 
sunlight for 24 h.  
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Solid state degradation study: 
Dry heat degradation studies: 
Hundred mg of the drug sample was kept in an oven at 60ºC for 8 h to study the heat 
degradation. A solution of 10 µg/ml of the dry heat degraded sample solution was prepared 
and the chromatogram was run. 
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HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHT (HPTLC) 
METHOD DEVELOPENT AND OPTIMIZATION  
MEHOD DEVELOPEMNT 
Bulk drug  :  ZMT supplied by Orchid health care Chennai 
Selection of solvent : The selected solvent must give some ideal properties like, the  
drug should be stable in the selected solvent.  Hence methanol 
was selected as the solvent for the drug. 
 
Selection of detection wavelength:  
The selection of proper wavelength is an important fact in the result of an HPTLC. 
The sensitivity of the HPTLC is depend on the wavelength selected and the UV detector. An 
ideal wavelength is the one that gives maximum absorbance and good response for the drug 
detected at lower concentration also. The drug was scanned under UV and 226 nm was 
selected as detection wavelength for the selected mobile phase.  
 
Selection of Mobile Phase: 
 Various mobile phase systems were tried for selecting the best mobile phase. 
Mobile Phase Rf value Observation 
Methanol:Water 0.0714 Spot migrated with solvent 
Ethyl acetate:Benzene 0.2727 Broad peak 
Ethylacetate:Methanol:Water 0.1 Spot did not moved 
Chloroform:Methanol 0.285 Symmetrical peak 
Ethyl 
acetate:Chloroform:Methanol 
0.197 Spot did not moved 
Chloroform:Acetic acid 0.05 Spot did not moved 
Chloroform:Acetone 0.2 Asymetrical peak 
 
  
Experimental 
 
KMCH College of Pharmacy  57 Dept. of Pharmaceutical Analysis  
 
Optimization: 
Fixed experimental parameters: 
 Injection   : Linomat 5  
 Detection   : CAMAG TLC scanner 
Information:  
 Stationary phase  : pre - coated silica gel GF aluminium sheets  
TLC  plate  
 Mobile phase   : chloroform: methanol: water (5:4:1 V/V/V) 
 Chamber saturation  : 15 min 
 Band length   : 6 mm   
 Application position  : 10 mm 
 Solvent front position  :  80 mm   
Instrument:  
            Number of track  : 8 
 Position of first track X : 15 mm 
 Distance between tracks :  10 mm  
 Scan start position Y   :       5.0 mm 
 Scan end position  : 85 mm 
 Slit dimensions  : 6 x 0.3 mm micro 
Optimize optical system :  light 
Scanning speed  : 20 mm/S 
Data resolution  : 100 µm/steps 
Measurement table: 
Wavelength   : 226 nm  
Lamp    : D2 & W 
Measurement type  : Remission  
Measurement mode  : Absorption  
Optical filter   : Second order  
Detector mode  : Automatic 
 
Preparation of standard solution: 
ZMT 2 mg is weighed accurately and transferred to a 10 ml standard flask. Dissolve 
it in few ml of methanol and made up the volume with the same. The final concentration of 
the standard solution was kept at 200 ng/ µL. 
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VALIDATIOD OF THE METHOD 
Linearity and range 
A stock solution of the drug was prepared at strength of 2 mg/10 ml. It was diluted to                              
prepare solutions containing 200-1000 ng/spot of the drug. The solutions were injected in 
triplicate into the HPTLC, keeping the injection volume constant (200 ng/ µL). 
 
Accuracy  
The accuracy of the method was evaluated in triplicate in different concentration 
levels 200-1000 ng/spot in bulk sample of ZMT. 
 
Precision 
Precision of the method was determined by 
a) Intra-day precision 
b) Inter-day precision 
c) Repeatability 
i) Repeatability of sample application  
ii) Repeatability of measurement 
 
a) Intra-day Precision 
Intra-day precision was found out by carrying out the analysis of the standard drug 
solution and one of sample to be analyzed at concentration 600 ng/spot and 800 ng/spot for 
three times on the same day. % RSD were calculated. 
 
b) Inter-day precision 
Inter-day precision was found out by carrying out the analysis of the drug solution at 
a concentration 600 ng/spot for two days and % RSD were calculated. 
 
c) Repeatability 
i) Repeatability of sample application 
Repeatability of the sample application was assayed by spotting 800 ng/spot of drug 
solution three times on a precoated TLC plate followed by the development and 
scanning, the % RSD was calculated 
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ii) Repeatability of measurement 
Repeatability of measurement of the peak area was determined by spotting 600 
ng/spot of the drug solution on a pre-coated TLC plate followed by the development. 
The separated spots were scanned three times without changing the position of the plate 
and the %RSD were calculated. 
 
 Limit of Detection (LOD) and Limit of Quantification (LOQ) 
In order to estimate the LOD and LOQ, blank methanol alone was spotted six times . 
Then the signal to noise ratio was determined.  The LOD was found to be 3:1 and the LOQ 
was 10:1. 
 
 Stability Studies 
When the developed chromatographic plate is exposed to atmosphere, the analyte is 
likely to decompose. Hence it is necessary to conduct stability studies.  
 
Ruggedness and robustness of the method 
Method robustness and ruggedness were determined by analyzing same sample at 
normal operating conditions and also by changing some operating analytical conditions such 
as mobile phase composition, instrument and analyst. 
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STRESS DEGRADATION STUDY 
 
Types of stress degradation proposed to study: 
 Liquid state degradation study. 
 Solid state degradation study. 
 
 Liquid state degradation proposed to study: 
 1. Base hydrolysis.  (0.1M NaOH) 
 2. Acid hydrolysis. (0.1M and 1M HCl) 
 3. Oxidation.  (3% H2O2) 
         4. Photolysis  
 
 Solid state degradation proposed to study: 
1. Dry heat degradation study (100°C). 
 
Forced degradation studies 
A stock solution containing 10 µg/ml of ZMT in methanol was prepared. Further 
diluted was made with Methanol. This solution was used for forced degradation to provide 
an indication of the stability indicating property and specificity of the proposed method. In 
all degradation studies the average peak area of ZMT after application (2000 ng/spot) 
obtained. In order to study the degradation products of ZMT using the HPTLC method most 
of the study was carried out by single development of the HPTLC plate in order to prevent 
the movement of the non-polar degradation products to the extreme end of the plate. 
 
1. Acid and base induced degradation studies: 
Acid decomposition studies were performed by refluxing the solution of drug 1M 
and 0.1M hydrochloric acid at 80°C for 8 h. The studies under alkaline conditions were 
carried out in 0.1M sodium hydroxide and the solution was refluxed for 8 h at 80°C. These 
were repeated at a lower temperature of 40°C keeping all other conditions constant. The 
resulting solutions were applied to HPTLC plate in such a way that final concentration 
achieved was 2000 ng/spot for both acid and degradation products and the chromatograms 
were run as described in section.  
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2. Hydrogen peroxide-induced degradation 
To study hydrogen peroxide induced degradation. Initial studies were performed in 
3% hydrogen peroxide at 80ºc for 8 h. For the HPTLC study, the resultant solutions were 
applied to TLC plate in such a way that final concentration achieved was 2000 ng/spot and 
the chromatograms were run as described in section. 
 
3. Dry heat- and wet heat-degradation 
The standard drug in solid form was placed in an oven at 100°C for 8 h to study the 
dry heat-degradation. The sample is then made into solution and a 2000 ng is spotted and the 
chromatogram were run as described. 
 
4. Photochemical degradation 
Ten µg/ml of the solution was kept at direct sunlight for 24 h and then a 2000 ng spot 
is made on TLC plate and the chromatogram were run as mentioned. 
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CHAPTER VII 
RESULTS  
HIGH PRESSURE LIQUID CHROMATOGRAPHY (HPLC) 
Table 1: System Suitability Parameters 
 
                  Parameters                           ZMT  
Number of theoretical plates                          12863 
HETP                          11.66 
Tailing factor                          1.09 
Capacity factor                          2.372 
Limit of detection LOD                          0.54 
Limit of quantification LOQ                          1.82 
Resolution                           4.294 
Linearity range                          2-10 µg / ml 
 
 
Table 2: Linearity and range 
 
Sl.No Concentration (µg/ml) Peak area 
1 2.0 281620 
2 4.0 552172 
3 6.0 837773 
4 8.0 1134687 
5 10.0 1395703 
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Fig 4: Linearity curve of ZMT 
 
Table 3: Interday precision 
Drug Concentration 
(µg/ml) 
Interday precision 
Peak area SD %RSD 
ZMT 
            4 546254 3365.15 0.6124 
            6 829900 4468.16 0.5388 
            8 1227985 7641.22 0.6222 
 
 
Table 4: Intraday precision 
Drug Concentration 
(µg/ml) 
Intraday precision 
Peak area SD %RSD 
ZMT 
4 567355 4386.00 0.7730 
6 846865 5010.37 0.5916 
8 1235532 11174.43 0.9044 
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Table 5: Solution stability 
Sl.No Drug Days %Assay 
1 
Standard ZMT 
Initial 99.42 
2 After 24 hr 99.08 
3 After 48 hr 98.74 
 
Limit of detection and limit of quantification 
Signal to noise ratio of 3:1 and 10:1 were obtained for the LOD and LOQ respectively.   
 
Table 6: LOD and LOQ of ZMT 
Parameter ZMT (ng/ml) 
LOD 0.54 
LOQ 1.83 
 
 
Table 7: Ruggedness (Day - 1, Analyst - 1) 
Method 
Precision 
Peak area Average 
area 
%Drug 
content 
Average SD %RSD 
Standard 837528      
Sample 1 826482 
832626 
98.68 
99.41 4456.74 0.5352 
Sample 2 835176 99.71 
Sample 3 834872 99.68 
Sample 4 829476 99.03 
Sample 5 837124 99.95 
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Table 8: Ruggedness (Day-2, Analyst – 2) 
 
Method 
Precision 
Peak area Average 
area 
%Drug 
content 
Average SD %RSD 
Standard 846865      
Sample 1 824719 
838187.2 
97.38 
98.50 13193.74 1.57408 
Sample 842731 99.51 
Sample 3 837246 98.86 
Sample 4 842476 99.48 
Sample 5 823764 97.27 
 
 
Table 9: Robustness testing of the method 
 
Parameters Modifications ZMT Recovery (%) 
pH 
3.0 96.43 
4.0 98.18 
Detection wavelength (nm) 
224 98.74 
230 99.82 
Flow rate (ml/min) 
0.8 97.46 
1.2 98.42 
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Fig 5: Chromatogram of 2 µg/ml of ZMT 
                             
    
Fig 6: Chromatogram of 4 µg/ml of ZMT 
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Fig 7: Chromatogram of 6 µg/ml of ZMT 
 
                         
  
Fig 8: Chromatogram of 8 µg/ml of ZMT 
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Fig 9: Chromatogram of 10 µg/ml of ZMT 
 
 
Table 10: Result of forced degradation studies of ZMT samples using the proposed 
method 
 
Stress condition/Duration/State Degradation (%) 
Acidic/1M HCl/8 h/Solution/80ºc 98.61 
Acidic/ 0.1M HCl/8 h/Solution/80ºc 84.18 
Basic/0.1M NaOH/8 h/Solution/80ºc 59.03 
Oxidation/3% H2O2 /8 h/Solution/80ºc 97.68 
Photolysis/Solution/Direct sunlight 74.37 
Dry heat/Solid/100ºc  in oven 32.23 
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   Fig 10: Chromatogram of ZMT subjected to acid degradation in 0.1M HCl  
 
 
                         Fig 11: Chromatogram of ZMT subjected to acid degradation in 1M HCl  
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Fig 12: Chromatogram of ZMT subjected to alkaline degradation in 0.1M NaOH 
 
 
Fig 13: Chromatogram of ZMT subjected to oxidative degradation in 3% H2O2 
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Fig 14: Chromatogram of ZMT subjected to photolytic degradation 
 
 
Fig 15: Chromatogram of ZMT subjected to dry heat degradation 
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Fig 16: Bar diagram of force degradation study 
 
     
 
Fig 17: Spectrum index for ZMT 
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                   Fig 18: Peak purity profile for ZMT 
Retention Time           : 9.2 min 
Impurity                       : Non Detected 
Peak purity index        : 1.00000 
Single point threshold : 0.999218 
                    
 
                 Fig 19: Peak purity curve for ZMT     
Retention Time           : 9.2 min 
Impurity                       : Non Detected 
Peak purity index        : 0.999659 
Single point threshold : 0.998673 
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HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY (HPTLC)  
 
Table 11: LINEARITY AND RANGE 
Concentration 
(ng/spot) 
ZMT 
Rf value Peak Area 
200 0.29 1759 
400 0.30 3917 
600 0.30 5297 
800 0.30 6670 
1000 0.30 7715 
 
 
                   
  
                                                  Fig 20: Calibration curve for ZMT 
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Inter Day and Intraday assay Precision (n=6) 
Table 12: Intra Day Precision 
 
Drug 
Concentration 
(ng/spot) 
Intraday precision 
Peak area SD %RSD 
ZMT 
600 1854 29.0057 1.5639 
800 3922 70.4651 1.8064 
1000 5261 63.8513 1.1979 
 
 
Table 13: Interday precision 
Drug 
Concentration 
(ng/spot) 
Inter day precision 
ZMT 
 Peak Area SD %RSD 
600 1956 30.6648 1.5891 
800 3692 71.5052 1.9747 
1000 6492 71.1641 1.0932 
 
Limit of detection and limit of quantification 
Signal to noise ratio of 3:1 and 10:1 were obtained for the LOD and LOQ respectively.   
Table 14: LOD and LOQ of ZMT 
Parameter ZMT         (ng/spot) 
LOD 40.8 
LOQ 138.2 
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Table 15: Solution stability 
 
Sl no Drug Days % Assay 
1 ZMT 
Initial 99.24 
After 24 h 99.09 
After 48 h 98.51 
 
 
Table 16: Ruggedness (Day-1, Analyst-1) 
Method 
Precision 
Peak area 
Average 
area 
% Drug 
content 
Average SD %RSD 
Standard 3997      
Sample 1 3917 
3911.6 
98.20 
99.01 0.7286 0.7358 
Sample 2 3856 98.41 
Sample 3 3992 99.68 
Sample 4 3920 99.82 
Sample 5 3873 98.96 
 
 
Table 17: Ruggedness (Day-2, Analyst-2) 
Method 
Precision 
Peak area Avg area 
% Drug 
content 
Average SD %RSD 
Standard 5412      
Sample 1 5297 
5262.4 
99.15 
98.86 0.4335 0.4384 
Sample 2 5316 99.28 
Sample 3 5237 98.84 
Sample 4 5198 98.16 
Sample 5 5264 98.89 
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Table 18: Robustness 
Parameters Modification % Recovery 
Mobile phase ratio 
5:3.5:1.5 96.83 
5:3.8:1.2 92.21 
Development distance 20 mm 95.65 
Detection wavelength 230 nm 97.52 
Slit dimension 5.00 X 0 .30m micro 97.28 
 
 
 
 
                                  Fig 21: Overlay spectrum of ZMT at 226 nm 
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                                                Fig 22:  Densitogram of ZMT 200 ng/spot 
 
 
 
                                              Fig 23: Densitogram of ZMT 400 ng/spot 
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                                              Fig 24: Densitogram of ZMT 600 ng/spot 
 
 
                                              Fig 25: Densitogram of ZMT 800 ng/spot 
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                                               Fig 26 : Densitogram of ZMT 1000 ng/spot 
 
 
                      Table 19: Result of Force Degradation Studies on ZMT 
Stress condition/Duration/State Degradation (%) 
Acidic / 1M HCl / 8 h / solution / 80ºc 97.42 
Acidic/0.1M HCl/8 h/solution/80ºc 86.64 
Basic / 0.1M NaOH / 8 h/solution / 80ºc 62.27 
Oxidation / 3% H2O2/ 8  h/solution / 80ºc 94.41 
Photolysis / 10µg/ml solution / direct sun 76.83 
Elevated temperature/ solid / 100ºc 33.59 
 
 
 
 
Results 
 
KMCH College of Pharmacy  81 Dept. of Pharmaceutical Analysis  
 
 
 
                      Fig 27: Densitogram of ZMT subjected to acid degradation in 1M HCl   
 
  
 
                      Fig 28: Densitogram of ZMT subjected to acid degradation in 0.1M HCl   
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              Fig 29: Densitogram of ZMT subjected to base degradation in 0.1M NaOH 
 
 
                  Fig 30: Densitogram of ZMT subjected toxidtaive degradation in 3% H2O2  
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Fig 31: Densitogram of ZMT subjected to photochemical degradation (direct sunlight) 
 
 
                    Fig 32: Densitogram of ZMT subjected to dry heat degradation (100ºC) 
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Fig 33: Bar diagram of forced degradation study 
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CHAPTER VIII 
DISCUSSION 
                                  
HIGH PRESSURE LIQUID CHROMATOGRAPHY (HPLC) 
DEVELOPEMNT   AND   OPTIMIZATION   OF   THE   STABILITY   
INDICATING   METHOD 
 
The stability-indicating RP-HPLC method for the determination of ZMT in the 
presence of degradation products was developed. ZMT was completely resolved from 
degradation products and impurities in a C-18 column (250 X 4.0 mm id, 5 µm particle size) 
using phosphate buffer (pH 3.5) and acetonitrile: methanol (50:50) as mobile phase (85:15) 
with a flow rate of 1 ml/ min and detected at a wavelength of 226 nm.  A Phenomenex C-18 
column was chosen because it has high carbon loading with very closely packed material to 
give high resolution compared to other C-18 column to develop a specific, accurate, precise 
and stability indicating RP-HPLC method for the estimation of ZMT. Different mobile 
phase systems were attempted to detect and quantify ZMT and its degradation product. The 
results of optimised mobile phase system (consisted of solvent A, phosphate buffer (pH 3.5), 
solvent B, acetonitrile: methanol (50:50) in the ratio of 85:15) was found to be satisfactory 
with respect to location and resolution of the peaks. The observed retention time for ZMT 
was found to be 9.2 min. The mobile phase saturation time was given about 15 min. 
Regression analysis of the calibration data for ZMT showed that the dependent variable 
(peak area) and the independent variable (concentration) were represented by the equation 
Y=14033x + (-1339). The correlation of coefficient (R
2
) obtained for ZMT was 0.9990.  
Thus a good linear relationship was observed in the concentration range of 2 – 10 µg/ml for 
ZMT. The assay of ZMT was found to be 99.42, which indicated high accuracy of the 
method. The absence of additional peaks in chromatogram indicated the non- interference of 
impurities.  
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METHOD VALIDATION 
System Suitability 
In order to determine the adequate resolution and repeatability of the proposed 
method, system suitability parameters including retention factor, selectivity, resolution and 
asymmetry factor were investigated and reported in Table 1.  
 
Linearity and range 
The calibration curves were linear in the range of 2-10 µg/ml, with a mean 
correlation coefficient, (R
2
) of 0.9990 and the mean of regression equation of Y=14033 X -
1339, which shows a perfect correlation which is reported in Table 2.  
 
Precision 
The intraday and interday variation of the method was evaluated at different 
concentration levels. The %RSD values of intraday and interday were <2% for the ZMT 
revealed that the proposed method is precise and is reported in Table 3 and 4. 
 
Limit of Detection (LOD) and Limit of Quantification (LOQ)  
The LOD was determined based on the signal-to-noise ratio and was determined 
using an analytical response of three times the background noise. The LOD for ZMT was 
found to be 0.54 µg/ml. The LOQ was determined as the minimum amount of analyte that 
was quantified above the baseline noise following the triplicate injection. The LOQ for ZMT 
was found to be 1.83 µg/ml, and the data are reported in Table 6. 
 
Solution Stability 
Stability of the solution was determined from the % assay of the solutions at 
different intervals. The study shows that the %RSD at different time was less than 2. Hence 
the sample solutions was found to be stable over the time (Table 5). 
 
Ruggedness and Robustness of the method 
According to ICH Guidelines, ruggedness and robustness assessment was performed 
during the development of an analytical procedure. By comparing interday and intraday 
precision results done by two analyst, the ruggedness of the method can be assessed. The 
%RSD value less than 2 for intraday and interday assay of ZMT, performed in the same 
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laboratory by two different analysts, indicated the ruggedness of the developed method as 
shown in Table 7 and 8. As shown in Table 9, robustness data of the mean obtained (n=6) 
for each factor studied, including that the selected factors remained unaltered by small 
variations of these parameters. 
 
FORCED DEGRADATION STUDIES 
A stock solution containing 10 µg/ml of ZMT was used for forced degradation to 
provide an indication of specificity of the proposed method. In all degradation studies like 
acid and base hydrolytic degradation, hydrogen peroxide (oxidation), dry heat and photolytic 
degradation, the average peak area of ZMT were obtained. ZMT were subjected to different 
ICH prescribed stress conditions. RP-HPLC analyses to identify the ZMT degradation 
products formed under stress conditions of hydrolysis, oxidation and photolysis. 
 
The degradation of ZMT was found to occur in hydrolytic, oxidative and to some 
extend in photolytic conditions. A stability-indicating RP-HPLC method was developed for 
the estimation of the ZMT in the presence of its degradation products. Hence a more 
complete degradation pathway of the drug was established than what known at present, by 
using a stress degradation technique and employing a RP-HPLC method shown in Table 10.  
 
Acid hydrolysis 
Acid hydrolysis of ZMT was done with 0.1 M and 1 M HCl at 80ºC for 8 h, where 
severe hydrolytic degradation was observed (Fig 9 and 10) with one of the degraded product 
eluted at a retention time of 10.3 min. The hydrolysis of ZMT is intense when compared to 
that of alkali.  
 
Base Hydrolysis 
On treatment with 0.1M NaOH for 8 h at 80ºC which resulted in the degradation of 
the ZMT. No degradation peak (Fig 11) was found along with the main ZMT peak.  
 
Oxidation 
Oxidative degradation was performed for ZMT with 3% hydrogen peroxide at 80ºC. 
One degraded peaks was observed at a retention time of 10.3 min (Fig 12). Oxidative 
treatment gives an intense degradation of ZMT. 
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Photolysis  
Photolytic degradation was done by exposing the ZMT to direct sunlight for 24 h, 
which results in the degradation of ZMT. There were no other co-eluting peaks were found 
along with the main peak (Fig 13). 
 
Dry heat-degradation 
The solid state studies revealed that the ZMT stable even after the exposure to 
elevated temperature of 100ºC for 8 h in oven. No degradation peaks were formed at this 
temperature and ZMT undergo degradation to a less extend only (Fig 14). 
 
HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY (HPTLC) 
DEVELOPEMNT   AND   OPTIMIZATION   OF   THE   STABILITY   
INDICATING   METHOD 
 
A HPTLC method was developed for the determination of ZMT in the presence of 
their degradation products generated during forced degradation studies. Use of HPTLC 
aluminium plates pre-coated silica gel 60F254 with chloroform: methanol: water in the 
volume ratio of 5:4:1 (v/v) resulted in good separation of ZMT and degradation products. A 
typical densitogram of ZMT is represented in Fig 25. Different mobile phases compositions 
were attempted to detect and quantify ZMT and its degradation product. The optimised 
mobile phase system consisted of Chloroform: Methanol: Water in the ratio of 5:4:1 (v/v/v). 
The observed Rf value was found to be 0.25. The complete separation of their degradation 
products and impurities was done at ambient temperature. Regression analysis of the 
calibration data for ZMT showed that the dependent variable (peak area) and the 
independent variable (concentration) were represented by the equation Y=7.503 X + 104.0.  
The correlation of coefficient (R
2
) obtained for ZMT was 0.9990.  Thus a good linear 
relationship was observed in the concentration range of 200-1000 ng/spot for ZMT. The 
assay of ZMT was found to be 99.24, which indicates high accuracy of the method. The 
absence of additional peaks in chromatogram indicates non-interference of impurities. 
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METHOD VALIDATION 
Linearity and range 
The calibration curves were linear in the range of 200-1000 ng/spot for each analyte, 
with a mean correlation coefficient (r
2
) of more than 0.999 and the mean of regression 
equations of Y=7.503 X + 104.0, which shows a perfect correlation. The mean values (± SD 
n = 6) of correlation coefficient, slope, and intercept were calculated and given in Table 11 
and Fig 19. 
 
Precision 
The intraday and interday variation of the method was evaluated by analyzing 5 
replicate samples of each at 3 different concentration levels (600, 800, and 1000 ng/spot). 
The %RSD values of within-day and day-to-day study were <2% for the ZMT revealed that 
the proposed method is sufficiently precise and is reported in Table 12 and 13. 
 
Limit of Detection (LOD) and Limit of Quantification (LOQ) 
The LOD was determined based on signal-to-noise ratio and was determined using 
an analytical response of three times the background noise. 
 
The LOD of ZMT was found to 
be 40.8 ng/spot. The LOQ was determined as the lowest amount of analyte that was 
reproducibly quantified above the baseline noise following triplicate injections. The 
resultant %RSD for these studies was ≤ 0.65%. The LOQ that produced the requisite 
precision and accuracy was found to be 138.2 ng/spot for ZMT and is reported in Table 14. 
 
Solution Stability 
Stability of the solution was determined from the % assay of the solutions at 
different intervals. The study shows that the %RSD at different time was less than 2. Hence 
the sample solutions was found to be stable over the time (Table 15). 
 
Ruggedness and robustness of the method 
According to ICH Guidelines, ruggedness and robustness assessment was performed 
during the development of an analytical procedure. By comparing interday and intraday 
precision results done by two analyst, the ruggedness of the method can be assessed. The 
%RSD value less than 2 for intraday and interday assay of ZMT, performed in the same 
laboratory by two different analysts, indicated the ruggedness of the developed method as 
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shown in Table 16 and 17. As shown in Table 18, robustness data of the mean obtained 
(n=6) for each factor studied, including that the selected factors remained unaltered by small 
variations of these parameters such as mobile phase ratio, slit dimension, pH and detection 
wavelength. 
 
FORCED DEGRADATION STUDIES 
A stock solution containing 2 mg ZMT in 10 ml methanol was prepared. This 
solution was diluted with methanol to get the Final concentration was 100 µg/µl. ZMT is 
used for forced degradation to provide an indication of specificity of the proposed method. 
In all degradation studies (acid- and base-hydrolytic degradation, hydrogen peroxide, dry 
heat and photolytic degradation) the average peak areas of ZMT after injection of six 
replicates were obtained. ZMT subjected to different ICH prescribed stress conditions. 
HPTLC analyses to identify the ZMT drug degradation products formed under stress 
conditions of hydrolysis, oxidation and photolysis. Hence a more complete degradation 
pathway of the drug was established than what known at present, by using a stress 
degradation technique and employing a HPTLC method shown in Table 19. 
 
Acid Hydrolysis 
ZMT undergoes severe hydrolytic degradation in acidic (0.1 M HCl and 1M HCl) 
condition at 80°C for 8 h. Complete degradation of ZMT was found on hydrolysis with 1M 
HCl. On degradation with 0.1M HCl, ZMT undergone degradation to a greater extend, 
which shows one additional peak with an Rf value of 0.21. The hydrolysis ZMT in acid was 
more intense as compared to that of alkali (Fig 26 and 27). 
 
Base hydrolysis 
On with 0.1M NaOH for 8 h at 80˚C which resulted in partial degradation of ZMT 
and two peaks were observed (Fig 28) at an Rf value of 0.25 and 0.21. The degradation peak 
(Fig 11) was well resolved from the main ZMT peak.  
 
Oxidation 
Oxidative degradation was performed for ZMT with 3% hydrogen peroxide at 80ºC 
for 8 h. The degradation was happened to a greater extend under oxidative condition. One 
degraded peak was observed at Rf value 0.21 (Fig 29). 
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Dry heat- degradation 
The solid state studies revealed that the ZMT is not stable after the exposure to 
elevated temperature of 100ºC for 8 h in oven. Degradation was happened to a lesser extend 
at this temperature and ZMT was found to be not stable. No co-eluting peaks found along 
with the main peak (Fig 31). 
 
Photolysis 
 No other co eluting peak was found with the main peaks in photolytic degradation 
which was kept in direct sunlight for 24 h, suggesting the specificity of the method for the 
estimation of ZMT in the presence of degradation products (Fig 30). The degradation of 
ZMT was happened to a greater extend in photolytic degradation. 
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CHAPTER IX 
CONCLUSION 
 
 The method was designed to validate the stability-indicating RP- HPLC and HPTLC 
method for the determination of ZMT in bulk drug. 
 
 The methods were validated by determining system suitability, specificity, precision, 
linearity, accuracy, stability, LOD, LOQ ruggedness and robustness parameters and 
found to be satisfactory. 
 
 The stability indicating features of the methods were demonstrated by the forced 
degradation of the active ingredient by acid hydrolysis, base hydrolysis, oxidative 
degradation, dry heat degradation and photolysis. 
 
 Forced degradants were shown to be non-interfering with the Rf value and Retention 
time of active ZMT. This reveals that the method is specific and selective. 
 
 The standard preparations in the range of 2 µg/ml to 10 µg/ml of the assay 
concentration were linear (Correlation coefficient, R
2 
=0.999, n = 6) in the developed 
RP-HPLC method. 
 
 The standard preparations in the range of 200 ng/spot to 1000 ng/spot of the assay 
standard concentration were linear (Correlation coefficient, R
2 
= 0.9989, n=6) in the 
developed HPTLC method.  
 
 The ruggedness of both the RP-HPLC and HPTLC method demonstrated that 
different operational and environmental variables had only a minimal influence on 
the test results. 
 
 It can be concluded that there is no other co eluting peak with the main peaks and 
hence both the RP-HPLC and HPTLC methods are specific for the estimation of 
ZMT in the presence of degradation products. Although no attempt was made to 
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identify the degradation products, the described method can be used as stability 
indicating method for the assay of ZMT in bulk drug form. 
 
 The method was completely validated showing satisfactory data for all the method 
validation parameters that were tested. The method can be employed as a stability 
indicating one, as the described method is capable of separating the drug from its 
degradation products. 
 
 It was concluded that, the developed RP-HPLC and HPTLC method is specific, 
accurate, precise, linear, and it may be used for the routine application for the 
determination of ZMT in the bulk drug forms in the presence of their degradation 
products. 
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